AU6172194A - Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens - Google Patents
Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigensInfo
- Publication number
- AU6172194A AU6172194A AU61721/94A AU6172194A AU6172194A AU 6172194 A AU6172194 A AU 6172194A AU 61721/94 A AU61721/94 A AU 61721/94A AU 6172194 A AU6172194 A AU 6172194A AU 6172194 A AU6172194 A AU 6172194A
- Authority
- AU
- Australia
- Prior art keywords
- packaging
- εaid
- recombinant molecule
- animal
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091007433 antigens Proteins 0.000 title claims description 123
- 239000000427 antigen Substances 0.000 title claims description 121
- 102000036639 antigens Human genes 0.000 title claims description 121
- 239000013598 vector Substances 0.000 title claims description 118
- 241000223997 Toxoplasma gondii Species 0.000 title claims description 89
- 241000710960 Sindbis virus Species 0.000 title claims description 71
- 230000002950 deficient Effects 0.000 title claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 238
- 230000001681 protective effect Effects 0.000 claims description 227
- 150000007523 nucleic acids Chemical group 0.000 claims description 221
- 241001465754 Metazoa Species 0.000 claims description 213
- 102000004169 proteins and genes Human genes 0.000 claims description 180
- 229960005486 vaccine Drugs 0.000 claims description 159
- 210000004027 cell Anatomy 0.000 claims description 150
- 241000710929 Alphavirus Species 0.000 claims description 145
- 150000001875 compounds Chemical class 0.000 claims description 138
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 128
- 241000700605 Viruses Species 0.000 claims description 127
- 239000002245 particle Substances 0.000 claims description 101
- 239000013604 expression vector Substances 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 85
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 claims description 78
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 78
- 238000004806 packaging method and process Methods 0.000 claims description 70
- 201000010099 disease Diseases 0.000 claims description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 66
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 52
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 48
- 230000001225 therapeutic effect Effects 0.000 claims description 46
- 208000015181 infectious disease Diseases 0.000 claims description 42
- 102000039446 nucleic acids Human genes 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 39
- 244000045947 parasite Species 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 35
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 31
- 238000012258 culturing Methods 0.000 claims description 29
- 230000004927 fusion Effects 0.000 claims description 29
- 241000894007 species Species 0.000 claims description 27
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 24
- 210000004102 animal cell Anatomy 0.000 claims description 24
- 241000002163 Mesapamea fractilinea Species 0.000 claims description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 21
- 125000001165 hydrophobic group Chemical group 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 19
- 230000002209 hydrophobic effect Effects 0.000 claims description 18
- 230000028327 secretion Effects 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 230000010076 replication Effects 0.000 claims description 17
- 239000012678 infectious agent Substances 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 15
- 241000271566 Aves Species 0.000 claims description 13
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 13
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 13
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 13
- 241000243990 Dirofilaria Species 0.000 claims description 12
- 241000233866 Fungi Species 0.000 claims description 10
- 108010024636 Glutathione Proteins 0.000 claims description 10
- 241000238631 Hexapoda Species 0.000 claims description 10
- 241000710961 Semliki Forest virus Species 0.000 claims description 10
- 244000078703 ectoparasite Species 0.000 claims description 10
- 229960003180 glutathione Drugs 0.000 claims description 10
- 244000000013 helminth Species 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 8
- 241000223996 Toxoplasma Species 0.000 claims description 8
- 244000000040 protozoan parasite Species 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 7
- 241000189163 Dipetalonema Species 0.000 claims description 6
- 230000000091 immunopotentiator Effects 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 241000243981 Onchocerca Species 0.000 claims description 5
- 241000244044 Acanthocheilonema Species 0.000 claims description 4
- 241000606660 Bartonella Species 0.000 claims description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- 241000223924 Eimeria Species 0.000 claims description 4
- 241000243234 Encephalitozoon Species 0.000 claims description 4
- 208000000832 Equine Encephalomyelitis Diseases 0.000 claims description 4
- 108010034145 Helminth Proteins Proteins 0.000 claims description 4
- 241001278020 Hepatozoon Species 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 235000005775 Setaria Nutrition 0.000 claims description 4
- 241000232088 Setaria <nematode> Species 0.000 claims description 4
- 241000223777 Theileria Species 0.000 claims description 4
- 241000244002 Wuchereria Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 241000223836 Babesia Species 0.000 claims description 3
- 241000244036 Brugia Species 0.000 claims description 3
- 201000008680 babesiosis Diseases 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 241000223935 Cryptosporidium Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 53
- 229920001184 polypeptide Polymers 0.000 description 49
- 102000004196 processed proteins & peptides Human genes 0.000 description 49
- 150000001413 amino acids Chemical class 0.000 description 45
- 238000004519 manufacturing process Methods 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 37
- 230000014616 translation Effects 0.000 description 24
- 238000013519 translation Methods 0.000 description 23
- 239000002609 medium Substances 0.000 description 21
- 108020001507 fusion proteins Proteins 0.000 description 18
- 102000037865 fusion proteins Human genes 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 102000005720 Glutathione transferase Human genes 0.000 description 17
- 108010070675 Glutathione transferase Proteins 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 230000002458 infectious effect Effects 0.000 description 16
- 108090000565 Capsid Proteins Proteins 0.000 description 15
- 208000035473 Communicable disease Diseases 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 238000013518 transcription Methods 0.000 description 15
- 230000035897 transcription Effects 0.000 description 15
- 241000243988 Dirofilaria immitis Species 0.000 description 13
- 208000030159 metabolic disease Diseases 0.000 description 13
- 239000012981 Hank's balanced salt solution Substances 0.000 description 12
- 208000030852 Parasitic disease Diseases 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 11
- 101001105440 Chlamydomonas reinhardtii Photosystem I reaction center subunit IV, chloroplastic Proteins 0.000 description 11
- 238000004520 electroporation Methods 0.000 description 11
- 108020005544 Antisense RNA Proteins 0.000 description 9
- 239000003184 complementary RNA Substances 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 8
- 241001468001 Salmonella virus SP6 Species 0.000 description 8
- 210000003527 eukaryotic cell Anatomy 0.000 description 8
- 210000000059 tachyzoite Anatomy 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 241000710942 Ross River virus Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 238000001638 lipofection Methods 0.000 description 7
- 102100026855 Cyclin-dependent kinase 5 activator 2 Human genes 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 102220072710 rs794729017 Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101800000515 Non-structural protein 3 Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 101800000980 Protease nsP2 Proteins 0.000 description 5
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 208000016097 disease of metabolism Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- -1 if not all Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001418 larval effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 208000003495 Coccidiosis Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 3
- 206010023076 Isosporiasis Diseases 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 3
- 108091036407 Polyadenylation Proteins 0.000 description 3
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000242677 Schistosoma japonicum Species 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 208000012851 brain cyst Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 101150055766 cat gene Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229940030156 cell vaccine Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000047823 human PLAT Human genes 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000036281 parasite infection Effects 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108010005636 polypeptide C Proteins 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- 208000004639 AIDS-Related Opportunistic Infections Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000256113 Culicidae Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000243212 Encephalitozoon cuniculi Species 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 2
- 241000243190 Microsporidia Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 206010057179 Toxoplasma infections Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- GJLXVWOMRRWCIB-MERZOTPQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=C(O)C=C1 GJLXVWOMRRWCIB-MERZOTPQSA-N 0.000 description 1
- UWQJHXKARZWDIJ-ZLUOBGJFSA-N Ala-Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O UWQJHXKARZWDIJ-ZLUOBGJFSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- ODWSTKXGQGYHSH-FXQIFTODSA-N Ala-Arg-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O ODWSTKXGQGYHSH-FXQIFTODSA-N 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
- NINQYGGNRIBFSC-CIUDSAMLSA-N Ala-Lys-Ser Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CO)C(O)=O NINQYGGNRIBFSC-CIUDSAMLSA-N 0.000 description 1
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 1
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- YUGFLWBWAJFGKY-BQBZGAKWSA-N Arg-Cys-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O YUGFLWBWAJFGKY-BQBZGAKWSA-N 0.000 description 1
- 241000244176 Ascaridida Species 0.000 description 1
- DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 1
- YWFLXGZHZXXINF-BPUTZDHNSA-N Asn-Pro-Trp Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 YWFLXGZHZXXINF-BPUTZDHNSA-N 0.000 description 1
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 1
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 1
- BKOIIURTQAJHAT-GUBZILKMSA-N Asp-Pro-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 BKOIIURTQAJHAT-GUBZILKMSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- 241000020089 Atacta Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000244038 Brugia malayi Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000893174 Chabertia ovina Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 241001126268 Cooperia Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000904768 Cyathostominae Species 0.000 description 1
- KLLFLHBKSJAUMZ-ACZMJKKPSA-N Cys-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N KLLFLHBKSJAUMZ-ACZMJKKPSA-N 0.000 description 1
- DZSICRGTVPDCRN-YUMQZZPRSA-N Cys-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N DZSICRGTVPDCRN-YUMQZZPRSA-N 0.000 description 1
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 1
- KJJASVYBTKRYSN-FXQIFTODSA-N Cys-Pro-Asp Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CC(=O)O)C(=O)O KJJASVYBTKRYSN-FXQIFTODSA-N 0.000 description 1
- IXPSSIBVVKSOIE-SRVKXCTJSA-N Cys-Ser-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O IXPSSIBVVKSOIE-SRVKXCTJSA-N 0.000 description 1
- KFYPRIGJTICABD-XGEHTFHBSA-N Cys-Thr-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N)O KFYPRIGJTICABD-XGEHTFHBSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241001126846 Encephalitozoon hellem Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 101150066516 GST gene Proteins 0.000 description 1
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 1
- MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RLFSBAPJTYKSLG-WHFBIAKZSA-N Gly-Ala-Asp Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O RLFSBAPJTYKSLG-WHFBIAKZSA-N 0.000 description 1
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 1
- VNBNZUAPOYGRDB-ZDLURKLDSA-N Gly-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN)O VNBNZUAPOYGRDB-ZDLURKLDSA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- BMWFDYIYBAFROD-WPRPVWTQSA-N Gly-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN BMWFDYIYBAFROD-WPRPVWTQSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- JSQIXEHORHLQEE-MEYUZBJRSA-N His-Phe-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JSQIXEHORHLQEE-MEYUZBJRSA-N 0.000 description 1
- XGBVLRJLHUVCNK-DCAQKATOSA-N His-Val-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O XGBVLRJLHUVCNK-DCAQKATOSA-N 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 101710084021 Large envelope protein Proteins 0.000 description 1
- YRRCOJOXAJNSAX-IHRRRGAJSA-N Leu-Pro-Lys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N YRRCOJOXAJNSAX-IHRRRGAJSA-N 0.000 description 1
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 1
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 1
- 241000255640 Loa loa Species 0.000 description 1
- IRNSXVOWSXSULE-DCAQKATOSA-N Lys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN IRNSXVOWSXSULE-DCAQKATOSA-N 0.000 description 1
- KSFQPRLZAUXXPT-GARJFASQSA-N Lys-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)C(=O)O KSFQPRLZAUXXPT-GARJFASQSA-N 0.000 description 1
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 1
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 1
- PRCHKVGXZVTALR-KKUMJFAQSA-N Lys-His-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCCCN)N PRCHKVGXZVTALR-KKUMJFAQSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- UQRZFMQQXXJTTF-AVGNSLFASA-N Lys-Lys-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O UQRZFMQQXXJTTF-AVGNSLFASA-N 0.000 description 1
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 1
- MEQLGHAMAUPOSJ-DCAQKATOSA-N Lys-Ser-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O MEQLGHAMAUPOSJ-DCAQKATOSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- OZVXDDFYCQOPFD-XQQFMLRXSA-N Lys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N OZVXDDFYCQOPFD-XQQFMLRXSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- GGXZOTSDJJTDGB-GUBZILKMSA-N Met-Ser-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O GGXZOTSDJJTDGB-GUBZILKMSA-N 0.000 description 1
- 241000710949 Middelburg virus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001147660 Neospora Species 0.000 description 1
- 241001126829 Nosema Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000710944 O'nyong-nyong virus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- FPTXMUIBLMGTQH-ONGXEEELSA-N Phe-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 FPTXMUIBLMGTQH-ONGXEEELSA-N 0.000 description 1
- JNRFYJZCMHHGMH-UBHSHLNASA-N Phe-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JNRFYJZCMHHGMH-UBHSHLNASA-N 0.000 description 1
- CMHTUJQZQXFNTQ-OEAJRASXSA-N Phe-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O CMHTUJQZQXFNTQ-OEAJRASXSA-N 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- VPVHXWGPALPDGP-GUBZILKMSA-N Pro-Asn-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPVHXWGPALPDGP-GUBZILKMSA-N 0.000 description 1
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 1
- OFGUOWQVEGTVNU-DCAQKATOSA-N Pro-Lys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OFGUOWQVEGTVNU-DCAQKATOSA-N 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
- IUXGJEIKJBYKOO-SRVKXCTJSA-N Ser-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N IUXGJEIKJBYKOO-SRVKXCTJSA-N 0.000 description 1
- HEYZPTCCEIWHRO-IHRRRGAJSA-N Ser-Met-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HEYZPTCCEIWHRO-IHRRRGAJSA-N 0.000 description 1
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 1
- BSXKBOUZDAZXHE-CIUDSAMLSA-N Ser-Pro-Glu Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O BSXKBOUZDAZXHE-CIUDSAMLSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- VFWQQZMRKFOGLE-ZLUOBGJFSA-N Ser-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O VFWQQZMRKFOGLE-ZLUOBGJFSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- CQNFRKAKGDSJFR-NUMRIWBASA-N Thr-Glu-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O CQNFRKAKGDSJFR-NUMRIWBASA-N 0.000 description 1
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- NWECYMJLJGCBOD-UNQGMJICSA-N Thr-Phe-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O NWECYMJLJGCBOD-UNQGMJICSA-N 0.000 description 1
- PJCYRZVSACOYSN-ZJDVBMNYSA-N Thr-Thr-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O PJCYRZVSACOYSN-ZJDVBMNYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 241000243774 Trichinella Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- SEXRBCGSZRCIPE-LYSGOOTNSA-N Trp-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O SEXRBCGSZRCIPE-LYSGOOTNSA-N 0.000 description 1
- ZAGPDPNPWYPEIR-SRVKXCTJSA-N Tyr-Cys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ZAGPDPNPWYPEIR-SRVKXCTJSA-N 0.000 description 1
- 241000571986 Uncinaria Species 0.000 description 1
- DDRBQONWVBDQOY-GUBZILKMSA-N Val-Ala-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DDRBQONWVBDQOY-GUBZILKMSA-N 0.000 description 1
- UEOOXDLMQZBPFR-ZKWXMUAHSA-N Val-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N UEOOXDLMQZBPFR-ZKWXMUAHSA-N 0.000 description 1
- WGHVMKFREWGCGR-SRVKXCTJSA-N Val-Arg-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WGHVMKFREWGCGR-SRVKXCTJSA-N 0.000 description 1
- BYOHPUZJVXWHAE-BYULHYEWSA-N Val-Asn-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N BYOHPUZJVXWHAE-BYULHYEWSA-N 0.000 description 1
- MBGFDZDWMDLXHQ-GUBZILKMSA-N Val-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C(C)C)N MBGFDZDWMDLXHQ-GUBZILKMSA-N 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000710951 Western equine encephalitis virus Species 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000000107 encephalitozoonosis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/45—Toxoplasma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Defective Sindbis Virus Vectors that Express Toxoplasma αondii P30 antigens
Field of the Invention
The present invention relates to novel recombinant live alphavirus vaccines and their use to protect animals from, for example, infectious or metabolic diseases. The present invention also relates to the use of alphavirus- based expression systems to produce such vaccines and other compounds capable of protecting animals from disease, including diseases caused by parasites, such as toxoplasmosis and heartworm.
Background of the Invention Despite intense efforts by laboratories throughout the world, there are currently essentially no effective vaccines against a number of infectious and metabolic diseases, including most, if not all, parasitic diseases. Although some promising antigens have been identified, there remains a need for an improved method to deliver efficacious protective compounds to an animal. In addition, there remains a need for a rapid, efficient and cost-effective method to produce efficacious protective compounds.
Live vaccines have been associated with longer-lasting immunity than inactivated vaccines. However, one disadvantage of live vaccines has been their ability to revert to virulence. In an attempt to overcome this problem, several viral and bacterial systems, such as poxviruses, herpesvirusas, adenoviruses, Salmonella , and
BCG (Bacillus Calmette-Guerin) , have been genetically manipulated to generate vectors containing heterologous antigen genes in order to immunize a host with a vaccine in which the antigens are presented in a "live" configuration (i.e., in which the antigens are exposed on the outside of a cell membrane or viral coat) . See, for example, the following two review articles: Esposito et al. , pp. 195- 247, 1989, Advances in Veterinary Science and Comparative Medicine , Vol. 33; Dougan et al., pp. 271-300, 1989, Advances in Veterinary Science and Comparative Medicine , Vol. 33. However, none of these systems has yet been commercialized.
Alphaviruses, which are members of the togavirus family, are attractive vaccine carriers because they have a wide host range. Alphavirus-based expression vectors are also attractive for the production of protective compounds in eukaryotic cells because alphaviruses have a wide host range, function in the cytoplasm and are capable of directing rapid and effective expression of viral structural genes under the control of alphavirus subgenomic promoters. Although some alphaviruses, such as Semliki Forest virus, are pathogenic, Sindbis virus has not been associated with natural disease in humans or animals. The genomes of several alphaviruses, including Sindbis virus, Semliki Forest virus, and Ross River virus, Venezuela equine encephalitis virus have been cloned and their nucleotide sequences determined; see, for example, Strauss et al., pp. 91-110, 1984, Virology, Vol. 133; Liljestrom et
al., pp. 4107-4113, 1991, J. Virology, Vol. 65; and Faragher et al., pp. 509-526, Virology , Vol. 163. Fig. 1 presents a schematic drawing of the location of the genes encoding the nonstructural and structural polypeptides of alphaviruses as well as of the transcription control regions, including the subgenomic promoter, that regulate the gene expression.
Both Sindbis and Semliki Forest viral expression vectors have been used to produce certain heterologous proteins in cell culture. The use of small Sindbis virus defective interfering (DI) RNA-based vectors, however, has been relatively ineffective; see, for example, Bredenbeek et al., pp. 297-310, 1992, Seminars in Virology, Vol. 3. Larger Sindbis virus vectors have been used to produce chloramphenicol acetyltransferase and tissue plasminogen activator (Xiong et al., pp. 1188-1191, 1989, Science , Vol. 243; Huang et al., pp. 85-91, 1989, Virus Genes , Vol. 3), and Semliki Forest virus vectors have been used to produce the human transferrin receptor, mouse dihydrofolate reductase, chick lysozyme, and beta-galactosidase (Liljestrom et al., pp. 1356-1361, 1991, Bio /Technology, Vol. 9). Several other proteins have been expressed transiently; see review by Bredenbeek et al., ibid . Liljestrom et al., ibid . , however, state that technical difficulties (e.g., low transfection rates) have precluded wide spread use of Sindbis virus vectors. Furthermore, the inventors are not aware of the use of alphavirus-based expression vectors to produce any compounds capable of
protecting animals from parasitic infections, such as those caused by protozoa, helminths, ectoparasites and/or fungi. Neither are the inventors are unaware of the use of a live alphavirus-based recombinant vaccine to protect an animal from infectious or metabolic diseases.
As such, there is a need for new and improved recombinant methods to produce efficacious protective compounds as well as a need for an improved vaccine delivery system to protect animals from metabolic disorders or infectious agents.
Summary of the Invention The present invention includes a new method to protect animals from disease using a recombinant virus particle vaccine comprising a packaging-defective recombinant molecule packaged in an alphavirus coat. When the recombinant virus particle vaccine of the present invention is administered to an animal, the virus particle is able to infect cells within the animal. Infected cells are able to express nucleic acid sequences present on the packaging- defective recombinant molecule to produce compounds capable of protecting the animal from a variety of diseases. Using methods taught in the present invention, vaccines can be generated that are capable of protecting an animal from any disease for which a protective protein or protective RNA • species can be produced. As such, the present invention is of extremely broad scope and includes a wide variety of vaccines that have a variety of applications.
One embodiment of the present invention is a recombinant virus particle vaccine that includes a packaging-defective recombinant molecule packaged in an alphavirus coat, the vaccine being capable of protecting an animal from disease when administered to the animal in an effective amount. The packaging-defective recombinant molecule includes a nucleic acid sequence that encodes a protective compound, such as a protective protein or protective RNA species, operatively linked to a packaging- defective alphavirus expression vector that is capable of directing expression, and preferably also replication, of the packaging-defective recombinant molecule. Animals administered the vaccine are able to produce the protective compound encoded by the packaging-defective recombinant molecule of the vaccine and thereby are protected from any disease that the protective compound can effectively neutralize or otherwise counteract.
Upon administration to an animal, preferred vaccines of the present invention are capable of effecting production of a protective protein that can elicit an immune response to protect the animal from, for example, an infectious agent. Other preferred vaccines are capable of eliciting production of antisense RNA molecules to protect an animal from disease. Particularly preferred vaccines contain nucleic acid sequences that encode at least one antigen, preferably Toxoplaεma gondii P30 or a functional equivalent thereof, capable of eliciting an immune response to protect an animal from toxoplasmosis.
The present invention also relates to a method for protecting an animal from disease by administering to such an animal an effective amount of a recombinant virus particle vaccine of the present invention. Vaccines can be administered in a variety of ways and can, but need not, include an immunopotentiator. According to one embodiment, a protective protein containing amino acids encoded by the nucleic acid sequence contained in the virus particle is also administered to the animal either prior to, following, or both prior to and following administration of the recombinant virus particle vaccine in order to enhance the immunogenic response.
The present invention also relates to a method to produce recombinant virus particle vaccines, which includes transfecting a packaging-defective recombinant molecule of the present invention into a host cell, preferably a mammalian, insect, or avian cell, in such a manner that culturing of the transfected cell yields recombinant virus particles. For example, a packaging-defective recombinant molecule can be co-transfected into a host cell with an alphavirus packaging vector that is capable of effecting packaging of the packaging-defective recombinant molecule into a virus particle, but is essentially incapable of self-packaging. Alternatively, the host cell to be transfected by the packaging-defective recombinant molecule can already contain the genetic information required to effect packaging of the packaging-defective recombinant molecule into a virus particle. Transfected cells are
subsequently cultured to produce virus particles, which are then recovered and formulated into a vaccine.
The present invention also includes a rapid and efficient method to produce, in a eukaryotic cell, compounds that are effective in protecting animals from parasitic infection. As such, one embodiment of the present invention is a therapeutic composition capable of protecting an animal from disease caused by a parasite when the composition is administered to the animal in an effective amount. In accordance with the embodiment, the composition is produced by a method that includes the steps of (a) culturing an animal cell transfected with a recombinant molecule to produce a compound capable of protecting the animal from the disease, (b) recovering the protective compound, and (c) formulating a therapeutic composition therefrom. Such a recombinant molecule includes at least one nucleic acid sequence encoding a protective compound operatively linked to an alphavirus expression vector. The recombinant molecule can be either packaging-defective or packaging-competent. Also included in the present invention is a method to protect an animal from a disease caused by a parasite that includes administering to the animal an effective amount of a therapeutic composition produced as disclosed above. Another aspect of the present invention involves
•recombinant molecules and the production thereof.
Recombinant molecules of the present invention can be generated by a method that includes the steps of (a)
producing a nucleic acid sequence encoding a protective compound, (b) producing an alphavirus expression vector capable of directing expression (and preferably also replication) of the recombinant molecule, and (c) operatively linking the nucleic acid sequence of (a) to the expression vector of (b) to obtain a recombinant molecule in which expression of the nucleic acid sequence is controlled by the expression vector. A recombinant molecule of the present invention is capable of directing expression of at least one protective compound when the recombinant molecule is transfected into an animal host cell. Such a recombinant molecule includes at least one nucleic acid sequence encoding the protective compound operatively linked to an alphavirus expression vector, the compound being capable of protecting an animal from disease, preferably from a disease caused by a parasite. Either a packaging-defective or packaging-competent recombinant molecule can be used to produce protective compounds by culturing recombinant cells containing such recombinant molecules. Packaging-defective recombinant molecules are preferably used in the production of recombinant virus or recombinant cell therapeutic compounds of the present invention. Packaging-defective recombinant molecules are used in recombinant virus particle vaccines of the present invention.
The invention also includes a recombinant molecule that includes an alphavirus expression vector operatively linked to a nucleic acid sequence encoding a fusion
protein, the fusion protein comprising a fusion segment joined to a protein heterologous to the alphavirus. Preferably the fusion protein also includes a signal segment capable of promoting secretion of the fusion protein.
Another embodiment is a recombinant molecule that includes a nucleic acid sequence encoding at least one antigen operatively linked to an alphavirus expression vector. The antigen, preferably a Toxoplasma antigen, a Dirofilaria antigen or a combination thereof, also includes a signal segment capable of secreting the antigen from an animal cell transfected by the recombinant molecule.
The present invention also includes a recombinant cell capable of producing at least one compound capable of protecting an animal from disease caused by a parasite. Such a recombinant cell comprises an animal cell transfected with a recombinant molecule capable of directing expression of the protective compound. Also included is a method to produce the protective compound that includes the steps of (a) culturing a recombinant cell of the present invention (i.e., an animal cell transfected with a recombinant molecule (i.e., a recombinant cell) to produce the protective compound, and (b) recovering the protective compound. Expression of nucleic acid sequences of the present invention is effected by alphavirus expression vectors to which the nucleic acid sequences are operatively linked. Preferred alphavirus expression vectors include Sindbis
virus expression vectors, Semliki Forest virus expression vectors, Ross River virus expression vectors, Venezuela equine encephalitis virus and hybrids thereof, with Sindbis virus expression vectors being more preferred. According to one embodiment, a nucleic acid sequence of the present invention is operatively linked to an alphavirus subgenomic promoter. Alphavirus expression vectors include packaging- defective and packaging-competent alphavirus expression vectors. Nucleic acid sequences of the present invention can encode one or more protective compounds of the present invention. Nucleic acid sequences of the present invention can be engineered to permit protective compounds produced by infected or otherwise transfected cells to remain inside the cell, to be secreted from the cell, or to be attached to the outer cell membrane. Preferred nucleic acid sequences are those that encode compounds capable of protecting an animal from a variety of diseases, such as those listed below. Particularly preferred nucleic acid sequences are those that encode compounds capable of protecting an animal from toxoplasmosis or heartworm.
One embodiment of the present invention is a nucleic acid sequence that encodes one of the following modified T. gondii P30 antigens: (a) a P30 antigen lacking amino terminal hydrophobic residues, (b) a P30 antigen lacking carboxyl terminal hydrophobic residues, or (c) a P30 antigen lacking both amino terminal and carboxyl terminal
hydrophobic residues. Also included are the proteins encoded by such nucleic acid sequences.
Preferred recombinant virus particle vaccines or other therapeutic compositions of the present invention are those that protect animals from diseases caused by protozoan parasites, helminth parasites, ectoparasites, fungi, bacteria, and viruses. Particularly preferred are those vaccines that protect animals from disease caused by infectious agents of the genera Toxoplasma , Dirofilaria , Acanthocheilonema , Babesia , Brxigia , Candida , Cryptococcuε , Cryptoεporidium , Dipetalonema , Eimeria , Encephalitozoon , Hepatozoon , Histoplasma , Isoεpora , Loa , Microsporidia , Neospora , Nosema , Onchocerca , Parafilaria , Plasmodium, Pneumocystiε , Rochalimaea , Setaria , Stephanofilaria , Theileria and Wuchereria and even more particularly, vaccines that protect animals against infection by T . gondii , Dirofilaria immitiε , and/or Cryptoεporidium .
A preferred embodiment of the present invention is a method to protect an animal from toxoplasmosis by administering to the animal an effective amount of a recombinant virus particle vaccine. The recombinant virus particle vaccine includes a recombinant molecule containing a nucleic acid sequence encoding a T. gondii P30 antigen or functional equivalent of the antigen, the nucleic acid sequence being operatively linked to a packaging-defective Sindbis virus expression vector capable of directing replication and expression of the recombinant molecule. The vaccine, when administered to an animal in an effective
amount, is preferably capable of infecting the animal so as to cause the production of P30 antigen which subsequently acts to elicit an immune response capable of protecting the vaccinated animal from toxoplasmosis. Another preferred method to protect an animal from toxoplasmosis includes administering to the animal an effective amount of a therapeutic composition produced by a method including the steps of (a) culturing an animal cell transfected with a recombinant molecule to produce a T. gondii P30 antigen, (b) recovering the antigen, and (c) formulating a therapeutic composition therefrom.
Brief Description of the Figures Fig. 1 is a schematic drawing depicting an alphavirus RNA genome and subgenomic RNA. Fig. 2 depicts a hydrophilicity plot of T . gondii P30 antigen.
Fig. 3 includes schematic drawings of several nucleic acid sequences that encode modified T. gondii P30 antigens.
Fig. 4 includes schematic drawings of Sindbis virus expression vectors SV1 and SV2 as well as a schematic drawing of a full-length Sindbis virus vector.
Fig. 5 schematically depicts the derivation of Sindbis virus packaging vector PV1.
Detailed Description of the Invention The present invention includes a recombinant virus particle vaccine, methods to produce the vaccine, and
methods to use the vaccine, preferably to immunize animals against infectious or metabolic diseases.
A recombinant virus particle vaccine of the present invention includes recombinant genetic information packaged in a viral coat. As such, a recombinant virus particle vaccine of the present invention is essentially a live vaccine and is advantageous because live vaccines are believed to confer more vigorous and longer-lasting immunity. While not being bound by theory, it is believed that such advantages are due to the ability of the genetic information carried by the virus particle vaccine to enter the cells of the vaccinated animal, replicate itself, and direct the expression of a protective compound, such as a protective protein (e.g. , an immunogenic protein, including carbohydrate, amino acid and/or other epitopes) or a protective RNA species (e.g., an antisense RNA species) for extended periods of time. Thus, such a vaccine need not be administered frequently and, in fact, the virus particle vaccine essentially can function as a self-booster. In addition, since the genetic information is packaged in a viral coat, the genetic information is protected from degradation and is injected into host cells by the normal route of infectivity, that is through normal cellular receptors that recognize and take up viruses. Recombinant virus particle vaccines of the present invention have a wide host range by virtue of their being able to infect multiple species and cell types. Moreover, since the genetic information present in the vaccine of the present
invention is packaging-defective (i.e., unable to effect packaging of the genetic information into a viral coat) , essentially no infectious virus is produced by the infected cells. A recombinant viral particle vaccine of the present invention is capable of delivering to a vaccinated animal a nucleic acid sequence of the present invention plus the proper alphavirus regulatory sequences so that the vaccinated animal can produce a protective compound encoded by that nucleic acid sequence. Essentially any nucleic acid sequence that encodes a protective compound, such as a protective protein or protective RNA species can be used in the present invention. As such, it is within the scope of the present invention to develop recombinant virus particle vaccines against a variety of infectious diseases such as those caused by protozoan parasite, helminth parasite, ectoparasite, fungal, bacterial, or viral infectious agents. It is also within the scope of the present invention to develop vaccines against a variety of metabolic diseases, such as Cushing's disease or cancer preferably using a vaccine encoding a protective RNA species.
A recombinant virus particle vaccine of the present invention includes a packaging-defective recombinant molecule packaged in an alphavirus coat. As used herein, an "alphavirus coat" is a viral coat containing at least one alphavirus structural polypeptide.
A recombinant molecule of the present invention includes an alphavirus expression vector which is operatively linked to a nucleic acid sequence encoding a protective compound of the present invention. A recombinant molecule of the present invention can be either packaging-competent or packaging-defective. A packaging- competent recombinant molecule includes an alphavirus expression vector that contains the genes and regulatory sequences necessary to effect packaging of the recombinant molecule into a virus (i.e., a packaging-competent alphavirus expression vector) . A packaging-defective recombinant molecule includes an alphavirus expression vector that is essentially incapable of effecting packaging of the packaging-defective recombinant molecule into a virus (i.e., a packaging-defective alphavirus expression vector) . The present invention includes RNA recombinant molecules as well as DNA recombinant molecules from which the RNA recombinant molecules can be transcribed. As used herein, "operatively linked" means that the nucleic acid sequence is joined (i.e., ligated) to the alphavirus expression vector in such a manner that regulatory signals present on the vector (e.g. , promoters) lead to the expression of the nucleic acid sequence, ultimately leading to the production of the corresponding protective compound (i.e., the compound encoded by the nucleic acid sequence) .
As used herein, a protective compound is a compound that is able to treat, ameliorate, or prevent disease, such as that caused by an infectious agent (e.g., a parasite) or
by a metabolic disorder. Protective compounds include protective proteins and protective RNA species. As used herein, a "protective protein" is a protein that, when produced by an animal administered a recombinant virus particle vaccine of the present invention or when produced in cell culture and subsequently administered to an animal, is able to treat, ameliorate, or prevent an infectious or metabolic disease in that animal. Similarly, a "protective RNA species", or a "protective RNA", is an RNA molecule that, when produced by an animal administered a recombinant virus particle vaccine of the present invention or when produced in cell culture and subsequently administered to an animal, is able to treat, ameliorate, or prevent an infectious or metabolic disease in that animal. As used herein, the phrases "to protect an animal from disease" and "to protect an animal from infection" refer to the ability of a protective compound of the present invention to treat, ameliorate, or prevent an infectious disease in an animal administered in an effective amount the compound and/or a virus particle vaccine capable of producing the compound, by for example, interfering with the infectious agent that causes the disease. Similarly, the phrase "to protect an animal from metabolic disease" refers to the ability of the protective protein or RNA species to treat, ameliorate, or prevent a metabolic disease in an animal administered an effective amount of the protective compound and/or a virus particle vaccine capable of producing the compound.
A protective protein of the present invention can be, for example, an immunogen that elicits an immune response capable of protecting an animal from the corresponding infectious disease. A protective protein can also be some other compound, such as a toxin, enzyme, antibody, or other binding protein, that is capable of neutralizing the infectious agent which causes the disease. A preferred protective protein of the present invention is an immunogen capable of eliciting both humoral and cell-mediated immunity to protect the animal from the disease. As used herein, protective proteins can include full-length proteins as well as modified versions of the protein in which amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide) , inserted, inverted, substituted and/or derivatized, such as by post- translational modification (e.g., glycosylation, phosphorylation, acetylation, carboxyl-terminal amidation) such that the modified version of the protein has a biological function substantially similar to that of the natural protein in its ability to protect an animal from disease (i.e., functionally equivalent to the natural protein) . Modifications can be accomplished by techniques known in the art including, but not limited to, direct modifications to the protein or modifications to the nucleic acid sequence encoding the protein using, for example, classic or recombinant DNA techniques to effect random or targeted mutagenesis. See, for example, Sambrook et al.. Molecular Cloning: A Laboratory Manual , Cold Spring
Harbor Labs Press, 1989. Protective proteins of the present invention, including modified versions thereof, can be identified in a straight-forward manner using any one of a number of screening techniques known to those skilled in the art including, but not limited to, functional assays and binding assays. In one embodiment, a modified, functionally equivalent T. gondii antigen can be selected by its ability to elicit an immune response capable of protecting an animal from toxoplasmosis. Protective protein immunogens of the present invention are of a sufficient size to form an epitope, a size that is typically at least about 7 to about 9 amino acids in length. As is appreciated by those skilled in the art, an epitope can include amino acids that naturally are contiguous to each other as well as amino acids that, due to the tertiary structure of the natural protein, are in sufficiently close proximity to form an epitope. Such epitopes can be identified, for example, by mutation analysis or by analysis of the three-dimensional structure of epitopes comprising an immunogen.
Protective proteins of the present invention can also include mimetopes, which include any compound that is able to mimic the ability of a protective protein of the present invention to protect an animal from parasitic disease. A mimetope can be a peptide that has been modified to decrease its susceptibility to degradation (for example, by replacing a scisεile peptide bond with a bond that cannot be efficiently cleaved by the endoprotease) but that still
retains its protective ability. Other examples of mimetopes include, but are not limited to, anti-idiotypic antibodies, or fragments thereof, that include at least one binding site that mimics one or more epitopes of a protective protein; and nucleic acids, that have a structure similar to at least one epitope of a protective protein of the present invention.
A protective RNA species of the present invention can be, for example, a recombinant molecule encoding a protective protein or RNA, an antisense RNA species, a ribozyme or an RNA-based drug that, when administered to an animal in an effective amount, is capable of protecting the animal from disease, and preferably from parasitic disease. Antisense RNA species and/or ribozymes can be used to reduce or prevent expression of parasitic genes, thereby protecting an animal from disease. As used herein, an RNA- based drug is any RNA molecule that is of sufficient size and/or structure to be able to interact with an intra- or extra-cellular component in order to prevent, treat, or ameliorate a disease otherwise caused by that component. Protective RNA species include RNA species that have been modified to, for example, increase their stability without substantially affecting the protective function of the RNA. For example, the backbone of an RNA species can be modified to decrease the susceptibility of the backbone to nucleases.
An isolated nucleic acid sequence of the present invention refers to any DNA or RNA molecule having a
nucleic acid sequence that encodes a protective protein or RNA species and that has been separated from its natural milieu. A nucleic acid sequence of the present invention can be isolated from natural sources, can be obtained by mutating natural isolates using classic or recombinant DNA techniques, or can be synthesized chemically.
Nucleic acid sequences of the present invention include those that encode naturally-occurring (i.e., native) protective proteins as well as those that encode functional equivalents thereof (i.e., functionally equivalent protective compounds) . As used herein, a "functionally equivalent" protective protein is a protein that has substantially the same biological activity as the naturally-occurring protective protein; that is, the functionally equivalent protective protein is capable of protecting an animal from infectious disease. Nucleic acid sequences that encode functionally equivalent protective proteins are herein referred to as functionally equivalent nucleic acid sequences and-include nucleic acid sequences having deletions, additions, inversions, and/or substitutions which, in spite of the modifications, encode protective proteins. The minimal size of a functionally equivalent nucleic acid sequence is the shortest length of nucleotides required to encode a protein capable of protecting an animal from an infectious disease.
Additional nucleic acid sequences of the present invention include nucleic acid sequences that encode RNA- based drugs, antisense RNA species or ribozymes. As used
herein, an "RNA-based drug" is any RNA molecule that is of sufficient size and/or structure to be able to interact with an intra- or extra-cellular component in order to prevent, treat, or ameliorate a disease otherwise caused by that component. As used herein an "antisense RNA" or "antisense RNA species" is any RNA molecule that is capable of substantially preventing expression of a detrimental protein. As such, a nucleic acid sequence encoding such an RNA can be of any size and structure that, when expressed, will yield an antisense RNA having the defined function.
A functionally equivalent nucleic acid sequence can be obtained using methods known to those skilled in the art. See, for example, Sa brook et al. , Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Labs Press, 1989. For example, nucleic acid sequences can be modified using a variety of techniques including, but not limited to, classic mutagenesis techniques and recombinant DNA techniques, such as site-directed mutagenesis, chemical treatment of a nucleic acid to induce mutations, restriction enzyme cleavage of a nucleic acid fragment, ligation of nucleic acid fragments, polymerase chain reaction (PCR) amplification and/or mutagenesis of selected regions of a nucleic acid sequence, synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" a mixture of nucleic acid sequences, and combinations thereof. Functionally equivalent nucleic acids can be selected from a mixture of modified nucleic acid sequences by screening for the function of the protein
or antisense RNA encoded by the nucleic acid sequence. A number of screening techniques are known to those skilled in the art including, but not limited to, functional assays and binding assays. In one embodiment, a nucleic acid sequence that encodes a functionally equivalent T. gondii antigen can be selected by its ability to encode a protein capable of eliciting an immune response that protects an animal from toxoplasmosis.
The present invention particularly involves recombinant virus particle vaccines that protect animals from infectious agents such as protozoan parasites, helminth parasites, ectoparasites, fungi, bacteria and viruses. As used herein, Microsporidia organisms are classified as protozoan parasites. As used herein, Pneumocystiε organisms are classified as fungi, although there is still controversy as to whether or not they should be classified as protozoa or fungi. Preferably, recombinant virus particle vaccines of the present invention protect animals from protozoan parasites, helminth parasites (such as nematodes, cestodes and trematodes, with filarial, ascarid, strongyle and trichostrongyle nematodes being more preferred) , ectoparasites, and/or fungi such as those that cause heartworm, malaria, coccidiosis, toxoplasmosis, or other AIDS-related opportunistic infections. More preferably, the vaccine is effective against at least one parasite of the genus Toxoplaεma , Dirofilaria , Acanthocheilonema , Babesia , Brugia , Candida , Cryptococcus , Cryptoεporidium ,
Dipetalonema , Eimeria , Encephalitozoon , Hepatozoon , Hiεtoplaεma , Iεoεpora , Loa , Microεporidia , Neoεpora , Noεema , Onchocerca , Parafilaria , Plaεmodium, Pneumocyεti , Rochalimaea , Setaria , Stephanofilaria , Theileria and Wuchereria . The vaccine is even more preferably effective against T. gondii , D. immitiε , or Cryptoεporidium parasites. Other suitable parasites against which to develop a vaccine include Aeluroεtrongyluε abεtruεuε , Ancyloεtoma εpp. , Angioεtrongyluε εpp. , Brugia malayi , Bunoεtomum spp. , Chabertia ovina , Cooperia spp. , Dictyocauluε εpp. , Dipetalonema εtreptocerca , Dipetalonema perεtans , Encephalitozoon cuniculi , Encephalitozoon hellem, Enterobiuε ver iculariε , Filaroideε εpp. , Haemonchuε εpp. , Loa loa , Manεonella ozzardi , Nematodiruε εpp. , Noεema corneum , Oeεophagoεtomum εpp. , Onchocerca volvuluε , Oεtertagia εpp. , Pneumocyεtiε carinii , Strongyloideε εpp. , Strongyluε εpp. , Trichinella εpiraliε , Trichoεtrongyluε εpp. , Trichuriε εpp. , Uncinaria εpp. , Wuchereria bancrofti , those nematodes of the order Ascaridida (Ascarids) and Cyathostominae (small strongyles of horses) .
Preferred nucleic acid sequences of the present invention are those that encode protective compounds that protect animals from infectious diseases caused by protozoan parasites, helminth parasites, ectoparasites, fungi, bacteria or viruses. More preferred nucleic acid sequences are those that encode protective proteins that protect animals from protozoan parasites, helminth parasites, ectoparasites, and/or fungi such as those that
cause heartworm, malaria, coccidiosis, toxoplasmosis, or other AIDS-related opportunistic infections.
A particularly preferred nucleic acid sequence of the present invention encodes a T . gondii antigen that is capable of eliciting an immune response to protect an animal from infection by T. gondii , which is a parasite that causes toxoplasmosis. T . gondii antigens useful in the present invention include, but are not limited to, tachyzoite antigens P30, P23, and P22, and other T. gondii antigens with molecular weights of about 25, about 28, about 30, about 35, about 41, about 54, about 66, and about 68 kilodaltons. As used herein, a T . gondii P30 antigen refers to a protein corresponding to the natural antigen as well as to proteins comprising modified forms of a natural P30 antigen capable of protecting an animal from toxoplasmosis. Similarly, any other antigen of the present invention referred to as "an" antigen includes a protein corresponding to the natural antigen as well as to modifications thereof capable of protecting an animal from the corresponding disease. Such modifications, or functional equivalents, can be isolated using methods taught herein; see, for example the Examples.
Additional particularly preferred nucleic acid sequences of the present invention encode at least one of the following proteins: D . immitiε P39, D . immitiε P22L, D . immitiε P22U, D . immitiε P20.5, D . immitiε P4 , D . immitis Di22 and/or D . immitiε proteases expressed in L3 and/or L4 larvae, as well as other helminth proteins sharing
significant ho ology with such D . immitiε proteins. A protein sharing significant homology with another protein refers to the ability of the nucleic acid sequences encoding such proteins to form stable hybridization complexes with each other under stringent hybridization conditions, as described, for example, in Sambrook et al., ibid . Grieve et al., in PCT International Publication No. WO 92/13560, published August 20, 1992, disclose a method to identify D . immitiε antigens capable of selectively binding to at least one component of immune serum that is capable of inhibiting heartworm development. U.S. Patent Application Serial No. 08/003,389, filed January 12, 1993, entitled "Immunogenic Larval Proteins", discloses a 39-kD D . immitiε protein (size determined by Tris glycine SDS- PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) ) , referred to herein as P39, and a nucleic acid sequence that encodes it. U.S. Patent Application Serial No. 08/003,257, filed January 12, 1993, entitled "Reagents and Methods for Identification of Vaccines", discloses 22-kD and 20.5-kD D . immitiε proteins (sizes determined by Tris glycine SDS-PAGE) , referred to herein as P22L and P20.5, and nucleic acid sequences that encode them. U.S. Patent Application Serial No. 08/109,391, filed August 19, 1993, entitled "Novel Parasitic Helminth Proteins", discloses D . immitiε P4 and D . immitiε P22U, as well as nucleic acid sequences that encode them. U.S. Patent Application Serial No. 08/060,500, filed May 10, 1993, entitled "Heartworm Vaccine", discloses a D . immitiε
Di22 protein and a nucleic acid sequence encoding it (included in GeneBank data base accession number M82811) ; Serial No. 08/060,500 is a continuation of U.S. Patent Application Serial No. 07/683,202, filed April 8, 1991. U.S. Patent Application Serial No. 08/153,554, filed November 16, 1993, entitled "Protease Vaccine Against Heartworm", discloses D . immitiε larval proteases; Serial No. 08/153,554 is a continuation of U.S. Patent Application Serial No. 07/792,209, filed November 12, 1991. A particularly preferred nucleic acid sequence for use in the present invention is one encoding a protective protein corresponding to the T . gondii P30 antigen, the major surface antigen of the tachyzoite stage of T . gondii infection. P30 is advantageous because it has been shown to protect mice from virulent T. gondii challenge (Khan et al., pp. 3501-3506, 1991, J. Immunol . , Vol. 147; Bulow et al., pp. 3496-3500, 1991, J. Immunol . , Vol. 147). The supply of native P30, however, has to date been too limited to make the isolation and use of such a native protein as a vaccine feasible. As such, the gene encoding the P30 antigen, which has been isolated and sequenced by Burg et al., pp. 3584-3591, 1988, J. Immunol . , Vol. 141. is particularly useful in the present invention. Table 1 corresponds to the coding region, and deduced amino acid sequence, of a full-length primary translation product of the T . gondii P30 antigen.
Table 1. Primary Translation Product of the T. gondii P30 Antigen
ATG TCG GTT TCG CTG CAC CAC TTC ATT ATT TCT TCT GGT TTT TTG ACG 48 Met Ser Val Ser Leu His His Phe lie lie Ser Ser Gly Phe Leu Thr 1 5 10 15 AGT ATG TTT CCG AAG GCA GTG AGA CGC GCC GTC ACG GCA GGG GTG TTT 96 Ser Met Phe Pro Lys Ala Val Arg Arg Ala Val Thr Ala Gly Val Phe • 20 25 30
GCC GCG CCC ACA CTG ATG TCG TTC TTG CGA TGT GGC GTT ATG GCA TCG 144 Ala Ala Pro Thr Leu Met Ser Phe Leu Arg Cys Gly Val Met Ala Ser 35 40 45
GAT CCC CCT CTT GTT GCC AAT CAA GTT GTC ACC TGC CCA GAT AAA AAA 192 Asp Pro Pro Leu Val Ala Asn Gin Val Val Thr Cys Pro Asp Lys Lys 50 55 60
TCG ACA GCC GCG GTC ATT CTC ACA CCG ACG GAG AAC CAC TTC ACT CTC 240 Ser Thr Ala Ala Val lie Leu Thr Pro Thr Glu Asn His Phe Thr Leu 65 70 75 80
AAG TGC CCT AAA ACA GCG CTC ACA GAG CCT CCC ACT CTT GCG TAC TCA 288 Lys Cys Pro Lys Thr Ala Leu Thr Glu Pro Pro Thr Leu Ala Tyr Ser 85 90 95 CCC AAC AGG CAA ATC TGC CCA GCG GGT ACT ACA AGT AGC TGT ACA TCA 336 Pro Asn Arg Gin lie Cys Pro Ala Gly Thr Thr Ser Ser Cys Thr Ser 100 105 110
AAG GCT GTA ACA TTG AGC TCC TTG ATT CCT GAA GCA GAA GAT AGC TGG 384 Lys Ala Val Thr Leu Ser Ser Leu lie Pro Glu Ala Glu Asp Ser Trp 115 120 125
TGG ACG GGG GAT TCT GCT AGT CTC GAC ACG GCA GGC ATC AAA CTC ACA 432 Trp Thr Gly Asp Ser Ala Ser Leu Asp Thr Ala Gly lie Lys Leu Thr 130 135 140
GTT CCA ATC GAG AAG TTC CCC GTG ACA ACG CAG ACG TTT GTG GTC GGT 480 Val Pro lie Glu Lys Phe Pro Val Thr Thr Gin Thr Phe Val Val Gly 145 150 155 160
TGC ATC AAG GGA GAC GAC GCA CAG AGT TGT ATG GTC ACG GTG ACA GTA 528 Cys lie Lys Gly Asp Asp Ala Gin -Ser Cys Met Val Thr Val Thr Val 165 170 175 CAA GCC AGA GCC TCA TCG GTC GTC AAT AAT GTC GCA AGG TGC TCC TAC 576
Gin Ala Arg Ala Ser Ser Val Val Asn Asn Val Ala Arg Cys Ser Tyr 180 185 190
GGT GCA GAC AGC ACT CTT GGT CCT GTC AAT TTG TCT GCG GAA GGA CCC 624 Gly Ala Asp Ser Thr Leu Gly Pro Val Asn Leu Ser Ala Glu Gly Pro 195 200 205
ACT ACA ATG ACC CTC GTG TGC GGG AAA GAT GGA GTC AAA GTT CCT CAA 672 Thr Thr Met Thr Leu Val Cys Gly Lys Asp Gly Val Lys Val Pro Gin 210 215 220
GAC AAC AAT CAG TAC TGT TCC GGG ACG ACG CTG ACT GGT TGC AAC GAG 720 Asp Asn Asn Gin Tyr Cys Ser Gly Thr Thr Leu Thr Gly Cys Asn Glu
225 230 235 240
AAA TCG TTC AAA GAT ATT TTG CCA AAA TTA ACT GAG AAC CCG TGG CAG 768 Lys Ser Phe Lys Asp lie Leu Pro Lys Leu Thr Glu Asn Pro Trp Gin 245 250 255
GGT AAC GCT TCG AGT GAT AAG GGT GCC ACG CTA ACG ATC AAG AAG GAA 816 Gly Asn Ala Ser Ser Asp Lys Gly Ala Thr Leu Thr lie Lys Lys Glu 260 265 270
GCA TTT CCA GCC GAG TCA AAA AGC GTC ATT ATT GGA TGC ACA GGG GGA 864 Ala Phe Pro Ala Glu Ser Lys Ser Val lie lie Gly Cys Thr Gly Gly 275 280 285
TCG CCT GAG AAG CAT CAC TGT ACC GTG AAA CTG GAG TTT GCC GGG GCT 912 Ser Pro Glu Lys His His Cys Thr Val Lys Leu Glu Phe Ala Gly Ala 290 295 300 GCA GGG TCA GCA AAA TCG GCT GCG GGA ACA GCC AGT CAC GTT TCC ATT 960 Ala Gly Ser Ala Lys Ser Ala Ala Gly Thr Ala Ser His Val Ser lie 305 310 315 320
TTT GCC ATG GTG ATC GGA CTT ATT GGC TCT ATC GCA GCT TGT GTC GCG 1008 Phe Ala Met Val lie Gly Leu lie Gly Ser lie Ala Ala Cys Val Ala 325 330 335
TG 1011
Another aspect of the present invention includes novel nucleic acid sequences that encode modified P30 antigens that are functionally equivalent to the natural P30 protein; that is, the modified antigens are capable of eliciting an immune response against T. gondii that protects the animal from toxoplasmosis. These nucleic acid sequences include, but are not limited to, modified nucleic acid sequences that encode P30 antigens from which amino acids possessing potentially troublesome hydrophobic groups (e.g. , at the amino and/or carboxyl termini, as necessary) have been removed, P30 antigens which can be secreted from the cells that produce them, and P30 antigens that are able to attach to the outer membranes of the cells that produce them.
When an alphavirus, such as a recombinant virus particle vaccine of the present invention, infects a cell, the virus takes over the host transcription and translation machinery but does not usually kill the cell. Thus, for
protective proteins that are often protective only when outside the host cell (e.g., immunogens) , it is preferred for such protective proteins to be secreted from the infected cell into a bodily fluid such as the bloodstream, to become attached to the outer membrane of the infected cell, or to be released from infected cells upon cell death.
In addition, the amino and carboxyl termini of natural T . gondii P30 antigens are hydrophobic, particularly in the regions spanning amino acid residues from about 1 through about 45 at the amino terminus and spanning amino acid residues from about 309 through about 336 at the carboxyl terminus (assuming that the methionine at position 1 corresponds to the first amino acid of the primary translation product shown in Table 1 and as shown in the hydrophilicity plot in Fig. 2) . While not being bound by theory, it is believed that these hydrophobic terminal residues of P30 antigen can lead to protein insolubility problems as well as to an inability to efficiently secrete P30 antigen from the cell in which it is produced. As such, a particularly preferred nucleic acid sequence of the present invention is one in which a nucleic acid encoding a signal segment (i.e., a signal segment nucleic acid) is joined to a nucleic acid sequence encoding a modified T . gondii P30 antigen from which hydrophobic amino and carboxyl terminal residues have been removed in such a manner as to effectively direct secretion of the encoded
protective protein from the cell infected by the recombinant virus particle vaccine.
In accordance with the present invention, a signal segment is a peptide that, when joined to a protein iri an appropriate manner, directs secretion of that protein from the cell in which the protein was produced. Signal segments, also referred to as signal sequence peptides, usually range in size from about 15 to about 30 amino acids, and are thought to initiate the transport of a protein across the membrane as an early step in the secretion process. In order to direct secretion of a protective protein of the present invention, the signal segment is joined to the amino terminus of the protective protein to be secreted in such a manner that the signal segment is capable of promoting secretion of the protective protein from the recombinant cell in which the protein is produced (e.g., the signal segment is placed "in-frame" with the protective protein) . Such a protein is encoded by a signal segment nucleic acid (encoding a signal segment) ligated to a nucleic acid sequence encoding the protective protein in such a manner that the protein produced by the ligated nucleic acid sequences is capable of being secreted.
A suitable signal segment for use in the present invention includes any signal segment capable of directing the secretion of a protein from a cell transfected by a recombinant molecule of the present invention. A nucleic acid encoding a signal segment can be produced by isolating
such a nucleic acid from a gene encoding a secreted protein or by chemically synthesizing such a nucleic acid. Preferred signal segments include, but are not limited to, tissue plasminogen activator (t-PA) , interferon, interleukin, growth hormone, histocompatibility and viral signal segments. More preferred signal segments include human t-PA, human interferon-α, mouse interleukin-3 and human major histocompatibility complex signal segments. A particularly preferred signal segment is a human t-PA signal segment, preferably including the initial about 23 amino acids of the t-PA primary translation product.
Another preferred nucleic acid sequence of the present invention is one in which a signal segment nucleic acid is substituted for the nucleic acid segment encoding the amino terminal hydrophobic residues of P30 and in which a nucleic acid segment encoding a "hook" or "anchor" is substituted for the nucleic acid segment encoding the carboxyl terminal hydrophobic residues of P30 in order to cause the functionally equivalent protective protein to be attached to the outer membrane of the cell that produces it. Suitable "hooks" include the "hook" carboxyl termini of Class II proteins, such as immunoglobulins.
Particularly preferred nucleic acid sequences of the present invention include nP30.1008 which encodes P30 antigen P30.336, corresponding to the amino acid sequence shown encoded in Table 1; nP30.873 which encodes P30.291; nP30.924 which encodes P30.308; nP30.789 which encodes P30.263; nP30.771 which encodes P30.257; nP30.867SS which
encodes P30.289SS; nP30.924SS which encodes P30.308SS; nP30.783SS which encodes P30.261SS; and nP30.771SS which encodes P30.257SS. Some of these nucleic acid sequences are depicted in Fig. 3. Note that although the nucleic acid sequences diagrammed in Fig. 3 are flanked by Xbal and XhoJ. restriction endonuclease sites, such nucleic acid sequences can be flanked by a variety of restriction enzyme sites to allow easy insertion of the sequences into a variety of expression and cloning vectors. P30.291 spans amino acids from about 46 through about 336 of P30, as numbered in the deduced amino acid sequence of Table 1, and as such, lacks amino terminal hydrophobic residues. P30.308 spans amino acids from about 1 through about 308, as numbered in the deduced amino acid sequence of Table 1, and as such, lacks carboxyl terminal hydrophobic residues. P30.263 spans amino acids from about 46 through about 308, as numbered in the deduced amino acid sequence of Table 1, and as such, lacks both amino and carboxyl terminal hydrophobic residues. P30.257 spans amino acids from about 49 through about 305, as numbered in the deduced amino acid sequence of Table 1, and as such, lacks P30 amino and carboxyl terminal hydrophobic residues. Prior to secretion, P30.289SS contains a t-PA signal sequence of about 23 amino acids joined to the amino terminus of a modified P30 protein that spans amino acids
• from about 48 through about 336 of P30, as numbered in the deduced amino acid sequence of Table 1, and as such, lacks
P30 amino terminal hydrophobic residues. (Note that Burg
et al. , ibid . , have predicted that T . gondii P30 is cleaved between amino acids 47 and 48 during maturation.) Prior to secretion, P30.308SS contains a t-PA signal sequence of about 23 amino acids joined to the amino terminus of a modified P30 protein that spans amino acids from about 1 through about 308 of P30, as numbered in the deduced amino acid sequence of Table 1, and as such, lacks P30 carboxyl terminal hydrophobic residues. Prior to secretion, P30.261SS contains a t-PA signal sequence of about 23 amino acids joined to the amino terminus of a modified P30 protein that spans amino acids from about 48 through about 308 of P30, as numbered in the deduced amino acid sequence of Table 1, and as such, lacks P30 amino and carboxyl terminal hydrophobic residues. Prior to secretion, P30.257SS contains a t-PA signal sequence of about 23 amino acids joined to the amino terminus of a modified P30 protein that spans amino acids from about 49 through about 305 of P30, as numbered in the deduced amino acid sequence of Table 1, and as such, - lacks P30 amino and carboxyl terminal hydrophobic residues. A detailed description of certain preferred nucleic acid sequences of the present invention is presented in the Examples section.
A nucleic acid sequence of the present invention can encode a compound capable of protecting an animal from a disease, including related diseases that are sufficiently similar that a protective compound targeted toward the given disease is also efficacious against related diseases. For example, a nucleic acid sequence of the present
invention can encode a compound capable of protecting an animal from disease by one type of parasite, including related parasites that are sufficiently similar to a given parasite that a compound targeted toward the given parasite is also efficacious against related parasites. Another embodiment is a nucleic acid sequence that encodes a multivalent protective compound that is targeted against more than one disease. As such it is possible to protect an animal against more than one (i.e., a combination of) disease. Such a nucleic acid sequence is produced by joining at least two nucleic acid sequences together in such a manner that the resulting sequence is expressed as a multivalent protective compound containing at least two protective compounds, or portions thereof, capable of protecting animals from diseases caused, for example, by at least one infectious agent. Examples of multivalent protective compounds include, but are not limited to, a T . gondii P30 antigen joined to a heartworm antigen, a T . gondii P30 antigen joined to an antigenic foot and mouth viral protein (e.g., VP1) , a T. gondii P30 antigen joined to a hepatitis viral protein, a T . gondii P30 antigen joined to an antigenic human immunodeficiency viral protein and a T. gondii P30 antigen joined to an antigenic feline immunodeficiency viral protein. As heretofore stated, the present invention includes recombinant molecules that can be either packaging- competent or packaging-defective. In accordance with the present invention, recombinant virus particle vaccines
include packaging-defective recombinant molecules. In contrast, both packaging-defective and packaging-competent recombinant molecules can be used in the production of protective compounds in vitro , as described in more detail below. As such, the present invention includes alphavirus expression vectors (and recombinant molecules including such vectors) that can be either packaging-defective or packaging-competent.
Alphaviruses are RNA viruses with a positive polarity RNA genome of about 12,000 nucleotides in length which sediments at about 49S; see Figure 1. The 5' two-thirds of the 49S RNA encodes alphavirus nonstructural polypeptides (e.g., nsPl, nsP2, nsP3 and nsP4, as denoted, for example, for Sindbis virus) required for replication and transcription. Replication of the 49S RNA results in a full-length negative polarity copy which serves both as a template for new genomic RNA and as a template for transcription of a 26S subgenomic RNA molecule corresponding to the 3' third of the genome, which contains the genes for alphavirus structural polypeptides (e.g., capsid polypeptide C, envelope glycopeptides El and E2, E3 and 6K, as denoted, for example for Sindbis virus) .
An alphavirus expression vector of the present invention can be either a DNA or RNA vector that contains alphavirus sequences that alone, or in concert with other
•sequences, are capable of directing expression of at least one protective compound of the present invention. The phrase "capable of directing expression of at least one
protective compound" refers to the ability of an alphavirus expression vector of the present invention, when placed in an appropriate host cell, to use the cellular machinery, as well as its own regulatory control regions and/or encoded enzymes, to effect transcription of genes present on the recombinant molecule, including the nucleic acid sequence to which the expression vector is operatively linked. Use of alphavirus expression vectors of the present invention is advantageous because such vectors are capable of directing the production of large amounts of biologically active compounds in the cytoplasm of cells transfected by such vectors or infected by recombinant virus particles including such vectors.
Packaging-competent alphavirus expression vectors can include genes encoding alphavirus nonstructural polypeptides and all of the alphavirus structural polypeptides (e.g. , capsid polypeptide C and envelope glycopolypeptides El and E2) . Alternatively, one or more of the structural genes can be encoded by the animal cell into which a recombinant molecule is transfected. (Such an animal cell can be produced, for example, by introducing such structural genes into the cell in a manner such that the genes are integrated into the cellular genome) .
Packaging-defective alphavirus expression vectors include alphavirus nonstructural genes but lack the ability to produce one or more functional structural polypeptides. Such inability may be due to lack of a gene encoding the structural polypeptide and/or to at least one mutation in
a structural gene such that a functional structural polypeptide cannot be produced. Such a packaging-defective recombinant molecule is able to be transcribed within a cell but cannot be packaged into an infectious virus unless a helper virus is present. That is, the phrases "packaging-defective" and "not capable of effecting packaging of said recombinant molecule" each refers to the inability of a packaging-defective alphavirus expression vector alone to accomplish packaging of a packaging- defective recombinant molecule into a virus since such an alphavirus expression vector does not contain a complete copy of the genes that encode the structural polypeptides that make up the viral coat. Preferred packaging-defective alphavirus expression vectors of the present invention retain the site required for packaging within the nonstructural polypeptide nsPl but lack the ability to produce one or more functional alphavirus structural polypeptides required to effect packaging of the recombinant molecule. The size of packaging-defective alphavirus expression vectors of the present invention is a function of the size of the recombinant molecules that contain the vectors since the recombinant molecules must be of a size appropriate to be packaged into viral particle vaccines according to the method described below. An alphavirus expression vector of the present invention is preferably able to direct replication of a recombinant molecule of the present invention, meaning that when the recombinant molecule is placed in an appropriate
host cell, the alphavirus expression vector is able to use the host cell machinery, as well as its own regulatory control regions and/or encoded enzymes, to effect replication of the recombinant molecule. In a preferred embodiment, the alphavirus expression vector includes genes encoding each of the alphavirus nonstructural polypeptides (e.g., nonstructural polypeptides nsPl, nsP2, nsP3 , and nsP4) , or functional equivalents thereof, and other regulatory control regions required for transcription and replication of the recombinant molecule. A preferred packaging-defective recombinant molecule of the present invention contains genes encoding each of the alphavirus nonstructural polypeptides (e.g., nonstructural polypeptides nsPl, nsP2, nsP3, and nsP4) , or functional equivalents thereof, and other signals required for transcription and replication of the recombinant molecule, but lacks the ability to produce one or more functional structural polypeptides (e.g., capsid polypeptide C or envelope glycopolypeptides -El or E2) . Such a recombinant molecule is able to be transcribed and replicated within a cell but cannot be packaged into an infectious virus unless a helper virus is present.
An alphavirus expression vector of the present invention can comprise any alphavirus expression vector and can be a hybrid between at least two alphavirus vectors. As used herein, a hybrid alphavirus expression vector refers to an expression vector that contains different regions from different alphavirus genomes that in
combination (i.e., ligated together) have the properties of an alphavirus expression vector of the present invention. Preferred alphavirus expression vectors include Sindbis virus expression vectors, Semliki Forest virus expression vectors, Ross River virus expression vectors, Venezuela equine encephalitis virus and hybrids thereof. Sindbis virus expression vectors are particularly preferred alphavirus expression vectors despite a statement by Liljestrom et al., ibid . , that technical difficulties (e.g., low transfection rates) have precluded wide spread use of Sindbis virus vectors. According to the present invention, either lipofection or electroporation permits straightforward manipulation of Sindbis virus vectors.
Sindbis virus vectors are particularly preferred because, unlike a number of other alphaviruses, Sindbis virus is not known to be associated with human disease. In addition, Sindbis virus has a wide host range. For example, Sindbis virus can infect mammalian, avian, insect, amphibian, and reptilian cells. Sindbis virus can also infect a number of cell types, including, but not limited to, Chinese hamster ovary cells, baby hamster kidney cells, quail (e.g. , QT-6) cells, chicken embryo fibroblasts, human tumor cells, mosquito and Droεophila cells. Sindbis virus can also be transmitted to vertebrate hosts, such as birds or mammals, by mosquitos.
Sindbis virus gene expression, which occurs in the cytoplasm of the cell, is quite efficient, rapid, and can be modulated. For example, Xiong et al., ibid . , reported
the production of up to 1 x 108 molecules of chloramphenicol acetyltransferase (CAT) per cell transfected with Sindbis virus expression vectors operatively linked to the CAT gene, when the cell was cultured for about 20 hr. Xiong et al. also reported that use of a replication temperature sensitive Sindbis virus vector led to modulated expression of CAT.
An alphavirus expression vector of the present invention preferably contains an alphavirus subgenomic promoter which, in natural alphavirus isolates, controls expression of viral structural polypeptide genes. In a preferred embodiment, expression of a nucleic acid sequence of the present invention is operatively joined to such an alphavirus subgenomic promoter. In one embodiment, at least one of the structural polypeptide genes of a natural alphavirus vector is deleted and a nucleic acid sequence of the present invention is joined to the vector such that expression of the nucleic acid sequence is placed under the control of alphavirus subgenomic promoter. In another embodiment, a nucleic acid sequence encoding the protective compound is operatively linked to the subgenomic promoter in combination with the structural genes. In yet another embodiment, the recombinant molecule can include a subgenomic promoter operatively linked to alphavirus structural genes and a second subgenomic promoter operatively linked to a nucleic acid sequence encoding the protective compound. Use of alphavirus subgenomic promoters are advantageous because they lead to high levels
of protein production in relatively short periods of time. However, it should be appreciated that other suitable promoters may also be used to control expression of a protective protein of the present invention. Suitable alphavirus subgenomic promoters of the present invention include any alphavirus subgenomic promoter, including hybrids thereof. A hybrid alphavirus subgenomic promoter is a promoter in which different regions thereof are derived from different alphavirus subgenomic promoters. Preferred subgenomic promoters include subgenomic promoters of Sindbis virus, Semliki Forest virus, Ross River virus, Middleburg virus, O'Nyong- nyong virus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, and hybrids thereof. More preferred alphavirus subgenomic promoters include Sindbis virus subgenomic promoters, Semliki Forest virus subgenomic promoters, Ross River virus subgenomic promoters, Venezuelan equine encephalitis virus and hybrids thereof, with Sindbis virus subgenomic promoters being even more preferred.
A recombinant virus particle vaccine of the present invention preferably includes a packaging-defective alphavirus vector in which at least one of the structural polypeptide genes of a natural alphavirus vector is deleted and a nucleic acid sequence of the present invention is joined to the vector such that expression of the nucleic acid sequence is under the control of alphavirus subgenomic promoter. Particularly preferred packaging-defective
Sindbis virus expression vectors include SV1 and SV2, which are depicted in Fig. 4. SV1 contains all the genes encoding nonstructural Sindbis virus polypeptides, the subgenomic promoter plus about 14 nucleotides downstream from the subgenomic RNA initiation site, and about 616 nucleotides at the 3 ' end of the Sindbis viral genome plus the poly(A) tail. SV2 is similar to SV1 except that SV2 contains only about 62 nucleotides of the 3 ' end of the Sindbis viral genome, thereby permitting the insertion of a larger nucleic acid sequence. Each of these vectors has a site for insertion of a nucleic acid sequence of the present invention as indicated.
In accordance with one embodiment of the present invention, a recombinant molecule can be produced by (a) isolating a nucleic acid sequence that encodes a protective protein, (b) isolating an alphavirus expression vector capable of directing transcription of a recombinant molecule of which the vector is a part, and (c) operatively linking the nucleic acid sequence to the expression vector to obtain a recombinant molecule in which expression of the nucleic acid sequence is controlled by the expression vector. Preferably, the alphavirus expression vector is also capable of directing replication of the recombinant molecule. Techniques for isolating nucleic acid sequences and
• expression vectors and for operatively linking a coding sequence to an expression vector are described in detail in
Sambrook et al., ibid. Since it is technically difficult
to perform recombinant techniques on RNA viruses, the RNA alphavirus vectors of the present invention are preferably converted into double-stranded cDNA copies using standard techniques. After genetic manipulations, such as' the insertion of a nucleic acid sequence of the present invention into an alphavirus expression vector, the resultant DNA recombinant molecule can be transcribed into an RNA recombinant molecule, for example, by the following method: The DNA recombinant molecule is inserted into a plasmid containing an RNA polymerase promoter and is transcribed in vitro in the presence of an appropriate RNA polymerase and other reagents to effect transcription. These techniques are described in greater detail in Sambrook et al., ibid. , and Xiong et al., ibid . Suitable RNA polymerase promoters include, but are not limited, to bacteriophage SP6, T7 and T3 promoters. A preferred RNA polymerase promoter is the bacteriophage SP6 promoter (e.g., Melton et al., pp. 7035-7056, 1984, Nucleic Acids Research , Vol. 12). The DNA recombinant molecule to be transcribed is preferably a linear or supercoiled molecule, with linear being more preferred.
Preferred recombinant molecules of the present invention include alphavirus expression vectors operatively linked to preferred nucleic acid sequences of the present invention. A recombinant molecule of the present invention can include one or more nucleic acid sequences operatively linked to one or more transcription control sequences (e.g., alphavirus subgenomic promoters). A preferred
recombinant molecule of the present invention includes a Sindbis virus expression vector and at least one nucleic acid sequence operatively linked to a Sindbis virus subgenomic promoter, the nucleic acid sequence encoding a T . gondii P30 antigen, a D . immitiε P39 antigen, a D . immitiε P22L antigen, a D . immitis P22U antigen, a D . immitiε P20.5 antigen, a D. immitiε P4 antigen, a D . immitis Di22 antigen (such as the Di22.RA antigen described in the Examples and/or an L3 and/or L4 D . immitis protease. Recombinant virus particle vaccines of the present invention include packaging-defective recombinant molecules that can be produced as heretofore disclosed using packaging-defective alphavirus expression vectors. For example, a packaging-defective recombinant molecule can be produced by (a) isolating a nucleic acid sequence that encodes a natural or functionally equivalent T . gondii P30 protein capable of protecting an animal from toxoplasmosis; (b) isolating a Sindbis virus expression vector that contains a subgenomic promoter and that encodes each of the Sindbis virus nonstructural polypeptides, but that is unable to encode at least one functional Sindbis virus structural polypeptide; and (c) operatively linking the P30 sequence to the subgenomic promoter so that expression of P30 is controlled by the subgenomic promoter. In one embodiment, at least one of the genes encoding Sindbis virus structural polypeptides C, El, or E2 is replaced by the sequence encoding a P30 antigen.
Preferred packaging-defective recombinant molecules of the present invention include alphavirus expression vectors operatively linked to preferred nucleic acid sequences of the present invention. Particularly preferred recombinant molecules of the present invention include SVl:nP30.1008, SVl:nP30.924, SV1:nP30.873 , SV1:nP30.789, SV1:nP30.771, SVl:nP30.924SS, SV1 :nP30.867SS , SV1 :nP30.783SS , SVl:nP30.771SS, SV2:nP30.1008, SV2:nP30.924, SV2:nP30.873 , SV2:nP30.789, SV2:nP30.771, SV2:nP30.924SS, SV2 :nP30.867SS, SV2:nP30.783SS, and SV2:nP30.771SS. The name of each of these particularly preferred recombinant molecules indicates the alphavirus expression vector (e.g., SV1) to which the nucleic acid sequence (e.g., nP30.1008) is operatively linked ( : ) . In accordance with the present invention, a recombinant virus particle vaccine can be produced by a method which includes the steps of (a) co-transfecting a host cell with a packaging-defective recombinant molecule and an alphavirus packaging vector; (b) culturing the transfected cell in an effective medium to produce a recombinant virus particle; (c) recovering the particle; and (d) formulating a vaccine therefrom. Preferably, the vaccine comprises a packaging-defective recombinant molecule packaged in a viral coat that includes alphavirus structural polypeptides such as capsid polypeptide (C) and two envelope glycopolypeptides (El and E2) . While not being bound by theory, it is believed that the recombinant molecule complexes with the capsid polypeptide to form an
intracellular icosahedral nucleocapsid which interacts with the cytoplasmic domains of the transmembrane envelope polypeptides El and E2, resulting in the budding of the virus vaccine at the plasma membrane. Since the packaging-defective recombinant molecules of the present invention do not themselves encode all the polypeptides required for packaging, the components of the viral coat can be provided by co-transfecting a host cell with both a packaging-defective recombinant molecule and an alphavirus packaging vector which acts as a helper virus to package the packaging-defective recombinant molecule. As used herein, "an alphavirus packaging vector" is an alphavirus-based vector that contains the genes that encode the structural polypeptides required for packaging of a packaging-defective recombinant molecule of the present invention into a virus particle. The packaging vector also contains sequences corresponding to the 5' and 3 ' ends of alphavirus RNA molecules which are important in transcription and replication. However, the alphavirus packaging vector is unable to direct its own packaging (i.e., self-package) because it lacks the site located within the nsPl gene thought to be necessary for packaging to occur. As such, packaging vectors of the present invention are much more useful for packaging packaging- defective recombinant molecules than are viral genomes containing the entire alphavirus RNA molecule since co- transfection of a host cell with a packaging-defective recombinant molecule and a packaging vector of the present
invention results in the desired recombinant virus particle vaccine but does not lead to the production of infectious alphaviruses (i.e., alphaviruses which are able to replicate and package themselves) . Suitable alphavirus packaging vectors include Sindbis virus packaging vectors, Semliki Forest virus packaging vectors, Ross River virus packaging vectors, Venezuelan equine encephalitis virus packaging vectors and hybrids thereof. Sindbis virus packaging vectors are preferred, particularly those that contain a minimal amount of genetic information to effect packaging. While not being bound by theory, it is believed that smaller packaging vectors are better because they are more efficient and more RNA can be produced per unit time. Particularly preferred packaging vectors are Sindbis virus packaging vectors that contain the structural polypeptide genes under the control of the subgenomic promoter and also contain replication and transcription signals at the 5' and 3'ends of Sindbis viral RNA. A particularly preferred Sindbis virus packaging vector is PV1, the production of which is depicted in Fig. 5.
According to the present invention, a recombinant virus particle vaccine can also be produced by (a) introducing, by transfection, a packaging-defective recombinant molecule into a host cell that already contains genes integrated into its chromosomal DNA and/or on extrachro osomal vectors that encode the structural polypeptides required to effect packaging of the packaging-
defective recombinant molecule (i.e., a host cell that is capable of packaging the packaging-defective recombinant molecule into a virus particle) ; (b) culturing the transfected cell in an effective medium to produce the virus particle; (c) recovering the virus particle; and (d) formulating a vaccine therefrom. Preferred genes are structural polypeptide genes of Sindbis virus, Semliki Forest virus, Ross River virus, Venezuelan equine encephalitis virus, with the structural polypeptide genes of Sindbis virus being more preferred. For example, Chinese hamster ovary cells containing genes encoding alphavirus structural polypeptides C, El, E2, E3, and 6K, or functional equivalents thereof of said polypeptides can be used as host cells. A number of host cells are suitable for recombinant virus particle vaccine production since alphaviruses have such wide host ranges. Suitable host cells include, but are not limited to, mammalian, insect, avian, reptilian, amphibian, and some insect- (e.g., mosquito and Droεophila ) cells. Preferred host cells include mammalian, insect, and avian cells. More preferred host cells include Chinese hamster ovary cells, baby hamster kidney cells, chicken embryonic fibroblasts, and mosquitos.
As used herein, transfection includes any means for introducing a nucleic acid sequence, expression vector, recombinant molecule, or packaging vector, into a host cell, including, but not limited to transformation, electroporation, microinjection, lipofection, adsorption,
and protoplast fusion. Preferred transfection techniques are lipofection and electroporation.
After transfection, transfected cells are cultured in an effective medium, using techniques such as those described in Xiong et al., ibid . As used herein, an effective medium refers to any medium in which the transfected cells can produce recombinant virus particle vaccines. An effective medium is typically an aqueous medium comprising assimilable carbohydrate, nitrogen and phosphate sources, as well as appropriate salts, minerals, metals and other nutrients, such as vitamins, growth factors and hormones. Culturing is carried out at a temperature, pH and oxygen content appropriate for the transfected cell. Such culturing conditions are well within the expertise of one of ordinary skill in the art. Examples of preferred effective media are included in the Examples section.
Recombinant virus particles can be recovered from the cultured transfected cells.using a combination of standard techniques such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, and hydrophobic interaction chromatography. A preferred recovery technique is Matrex® Cellufine™ Sulfate Media & Virus Recovery System, available from A icon Inc. , Danvers, MA.
Due to the nature of the recombinant molecules and packaging vectors of the present invention, essentially no infectious virus is formed (i.e., the probability of
forming infectious virus is less than about 1 x 10"°) , thus simplifying recovery of recombinant virus particle vaccines. Sindbis virus recombinant molecules and packaging vectors are particularly preferred since, even if a small amount of infectious Sindbis virus is produced, the virus is safe.
Preferably, a recombinant virus particle of the present invention is recovered in "substantially pure" form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the recombinant virus particle as a vaccine without substantial negative side effects. One embodiment of a substantially pure virus particle is a cell lysate containing the virus particle that generates substantially no side effects when administered to an animal in an effective amount to protect the animal from disease. It is within the scope of the present invention to recover recombinant virus particles having a purity of up to and including about 99 percent.
A recombinant virus particle vaccine of the present invention, when administered to an animal in an effective amount, infects the cells of the animal (in a manner essentially harmless to the animal) and directs the production of a protective compound able to protect the animal from an infectious or metabolic disease. Preferred recombinant virus particle vaccines are those that protect animals from infection by the infectious agents heretofore disclosed. Particularly preferred vaccines are those that protect animals from toxoplasmosis and/or heartworm.
A preferred recombinant virus particle vaccine of the present invention includes a packaging-defective recombinant molecule packaged in a Sindbis virus coat in which the recombinant molecule contains a nucleic acid sequence encoding a T . gondii and/or a D . immitis antigen capable of protecting an animal from toxoplasmosis and/or heartworm operatively linked to a Sindbis virus expression vector. More preferred recombinant virus particle vaccines (VPVs) include: VPV SV1:nP30.1008, VPV SV1:nP30.924, VPV SVl:nP30.873, VPV SVl:nP30.789, VPV SVl:nP30.771, VPV SVl:nP30.924SS, VPV SVl:nP30.867SS, VPV SV1:nP30.783SS, VPV SVl:nP30.771SS, VPV SV2:nP30.1008, VPV SV2:nP30.924, VPV SV2:nP30.873, VPV SV2:nP30.789, VPV SV2:nP30.771, VPV SV2:nP30.924SS, VPV SV2:nP30.867SS, VPV SV2:nP30.783SS, and VPV SV2:nP30.771SS. Each of these vaccines includes the designated recombinant molecule packaged in a Sindbis virus coat. For example, vaccine VPV SVl:nP30.1008 includes recombinant molecule SVl:nP30.1008 packaged in a Sindbis virus coat; recombinant molecule SVl:nP30.1008 contains a nucleic acid sequence that encodes a T . gondii P30 antigen of 336 amino acids that is operatively linked to alphavirus expression vector SV1.
Recombinant virus particle vaccines of the present invention can be used to protect animals from a variety of diseases, including infectious and metabolic diseases. When administered to an animal, the recombinant virus particle vaccine infects cells within the immunized animal and directs the production of a protective protein or RNA
species that is capable of protecting an animal from disease. For example, a T. gondii antigen will protect an animal from toxoplasmosis, a feline or human immunodeficiency virus (FIV or HIV, respectively) antigen will protect an animal from FIV or HIV infection, a D . immitiε antigen will protect an animal from heartworm, a Coccidia antigen will protect an animal from coccidiosis, a Plaεmodium falciparum antigen will protect an animal from malaria, a Cryptoεporidium antigen will protect an animal from enteric disease, an Encephalitozoon cuniculi antigen will protect an animal from encephalitozoonosis, and a
Pneumocyεtiε antigen will protect an animal from pneumonia.
Vaccines of the present invention can be administered to any animal, preferably to mammals, birds and insects, and more preferably to humans, cats, dogs, sheep, pigs, cattle, horses, poultry, ferrets, and other pets and/or economic food animals. Particularly preferred animals to protect include humans, cats and dogs. A preferred vaccine is one that, when administered to an animal, is preferably able to elicit (i.e., stimulate) the production of very high antibody titers as well as a high-level cellular immune response to the protective protein encoded by the nucleic acid sequence. Administration of a vaccine containing multiple nucleic acid sequences targeting multiple infectious agents can protect the vaccinated animal from those multiple infectious diseases.
Vaccines can be formulated in an aqueous balanced salt solution, or other excipients as disclosed below, that the
animal to be vaccinated can tolerate. In one embodiment of the present invention, the vaccine can also include an immunopotentiator, such as an adjuvant or a carrier. One advantage of live virus-based vaccines, such as the recombinant virus particle vaccines of the present invention, is that adjuvants and carriers are not required to produce an efficacious vaccine. However, it should be noted that use of immunopotentiators is not precluded by the present invention. Adjuvants are typically substances that generally enhance the immune response of an animal to a specific antigen. Suitable adjuvants include, but are not limited to, Freund'ε adjuvant; other bacterial cell wall components; aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins; viral coat proteins; other bacterial-derived preparations; gamma interferon; block copolymer adjuvants, such as Hunter's Titermax adjuvant (Vaxcel™ , Inc. Norcross, GA) ; Ribi adjuvants (available from .Ribi ImmunoChem Research, Inc., Hamilton, MT) ; and saponins and their derivatives, such as Quil A (available from Superfos Biosector A/S, Denmark) .
Carriers are typically compounds that increase the half-life of a vaccine in a vaccinated animal. Suitable carriers include, but are not limited to, polymeric controlled release formulations, biodegradable implants, liposomes, bacteria, other viruses, oils, esters, and glycolε.
In order to protect animals from a disease, a recombinant virus particle vaccine of the present invention is administered in an effective amount, wherein an "effective amount" is an amount that allows the animal to produce sufficient protective protein or RNA species to protect itself from the disease. For example, when the protective protein is a T . gondii antigen, the recombinant virus particle vaccine is administered according to a protocol that results in the animal producing a sufficient immune response to protect itself from toxoplasmosis. The administration protocol includes individual dose size, number of doses, frequency of dose administration, and mode of administration. A suitable single dose of the vaccine is a dose that is capable of protecting an animal from a disease when administered one or more times over a suitable time period. A preferred single dose of the vaccine is from about 1 x 104 to about 1 x 106 virus plaque forming units (pfu) per kilogram (kg) body weight of the animal. Booster vaccinations can be administered from about 2 weeks to several years after the original vaccination. Preferably booster vaccinations are administered when the immune response of the animal becomes insufficient to protect the animal from disease. A preferred administration schedule is one in which from about 1 x 10 to about 1 x 10° virus plaque forming units per kilogram (kg) body weight of the animal are administered from about 1 to about 2 times over a time period of from about 12 to about 18 months. Modes of administration can include, but
are not limited to, subcutaneous, intradermal, intravenous, nasal, oral, transdermal and intramuscular routes.
The efficacy of a recombinant virus particle vaccine of the present invention to protect an animal from disease can be tested in a variety of ways including, but not limited to, detection of protective protein or RNA species within the vaccinated animal or challenge of the vaccinated animal with an appropriate infectious agent to determine whether the animal is now resistant to the disease caused by such an agent. When the protective protein is an immunogen, it is also possible to determine vaccine efficacy by measuring antibody production by the animal in response to the immunogen (using either the immunogen or corresponding infectious agent as the target) and/or determining the ability of immune response cells (e.g. splenocytes) to respond to the infectious agent at various effector:target ratios.
One method to determine the ability of a nucleic acid of the present invention to encode a protective protein capable of eliciting an immune response against a disease, such as toxoplasmosis, is as follows. A recombinant molecule of the present invention is transfected into a host cell, preferably into a mammalian, insect, or avian cell. The host cell is cultured under conditions that promote production of the protective protein (e.g., a T . gondii P30 antigen) , which subsequently can be recovered from the culture. The recovered protective protein is then injected one or more times into an animal, such as a
rabbit, in a manner to promote the production of antibodies against the protective protein. Serum from the rabbit is subsequently recovered and tested for its ability to bind to, for example, the recovered protective protein, the corresponding native protective protein, and the corresponding infectious agent, with affinities that suggest that the nucleic acid encodes a suitable immunogen. For example, in the case of a T. gondii P30 antigen, the serum is tested against recovered P30 antigen, native T . gondii P30 antigen, and T. gondii tachyzoite parasites.
In one embodiment of the present invention, a recombinant virus particle vaccine, preferably one encoding a T . gondii antigen, and more preferably VPV SVl:nP30.1008 is administered subcutaneously to an animal, preferably a mammal, one or more times over a time period of from about 2 to about 4 weeks. Vaccine efficacy can be measured, for example, by determining whether the serum of the vaccinated animal contains antibodies that react with either a T . gondii parasite or the T . gondii antigen encoded by the nucleic acid sequence in the vaccine and/or, preferably, by challenging the animal with a dose of T . gondii parasites and determining if the animal develops toxoplasmosis. Protection can be monitored, for example, by mortality or by assaying for brain cysts. In accordance with one embodiment of the present invention, the efficacy of a recombinant virus particle vaccine of the present invention may be improved by co- administering the recombinant virus particle vaccine with
a protective compound encoded by the nucleic acid sequence of the recombinant virus particle vaccine. While not being bound by theory, it is believed that administration of a protective protein in conjunction with a recombinant virus particle capable of producing the protein may boost particularly the antibody titer. The protective protein can be administered prior to, concomitant with, and/or following administration of the recombinant virus particle vaccine. The protective protein can be either native (naturally-occurring) , synthetic, or recombinant. The protective protein can be a natural protein or functional equivalent thereof. The protective protein should be substantially pure, meaning that the protein is sufficiently pure to allow for effective use of the protective protein as a vaccine; i.e., the protein does not cause substantial side effects. The protective protein can be joined (i.e., conjugated) to a carrier or other material that enhances the immunogenicity of the protective protein. Suitable protective proteins, as well as preferred methods to produce such proteins, are disclosed below. In one embodiment, a recombinant virus particle vaccine containing a nucleic acid sequence encoding a T . gondii P30 antigen is administered with a sufficiently pure T . gondii P30 antigen, such as, but not limited to, a native P30 antigen (Khan et al., ibid . , Bulow et al., ijbid.), a recombinant P30 antigen such as P30.336, P30.308, P30.291, P30.289, P30.263, P30.261, P30.257; or a fusion protein between a recombinant P30 antigen and a fusion segment, such as GST-
P30.336, GST-P30.308, GST-P30.291, GST-P30.289, GST- P30.263, GST-P30.261 or GST-P30.257, which are described in more detail below.
The present invention also includes a rapid and efficient method to produce, in eukaryotic cells, compounds protective against parasitic infection. As such, the present invention includes recombinant molecules that are capable of directing the expression of at least one compound capable of protecting an animal from parasitic disease (i.e., disease caused by a parasite) when the recombinant molecule is transfected into an animal cell (i.e., introduced into an animal cell such that the transfected cell is capable of producing the protective compound) . As heretofore stated, a recombinant molecule of the present invention includes at least one nucleic acid sequence encoding such a compound operatively linked to an alphavirus expression vector. Suitable and preferred nucleic acid sequences include those heretofore cited for use in recombinant virus particle vaccines that are capable of protecting an animal from one or more parasitic diseases, including nucleic acid sequences that encode one or more protective proteins, one or more protective RNA species, one or more protective proteins including a signal segment, one or more protective proteins including a fusion segment, and one or more protective proteins including both a signal segment and a fusion segment.
A nucleic acid sequence encoding a fusion protein refers herein to a nucleic acid sequence encoding a
protective protein that includes at least one fusion segment attached to the protective moiety of the protective protein. Such a protein can also include a signal segment if secretion of such a protein is desired. Inclusion of a fusion segment in a protective protein can enhance the protective protein's stability during production, storage and/or use. Depending on the segment's characteristics, a fusion segment can also act as an immunopotentiator to enhance the immune response mounted by an animal immunized with a protective protein containing such a fusion segment. Furthermore, a fusion segment can function as a tool to simplify purification of a protective protein, such as to enable purification of the resultant fusion protein using affinity chromatography. A suitable fusion segment can be a domain of any size that has the desired function (e.g., increased stability, increased immunogenicity, and/or purification tool) . It is within the scope of the present invention to use one or more (i.e., a combination thereof) fusion segments. Fusion segments can be joined to amino and/or carboxyl termini of the protective portion of the protective protein. The linkage between fusion segments and the protective portions of protective proteins can be susceptible to cleavage in order to enable straight-forward recovery of the protective portions of such protective proteins.
Preferred fusion segments for use in the present invention include a glutathione binding domain, such as Schistosoma japonicum glutathione-S-transferase (GST) or a
portion thereof capable of binding to glutathione; a metal binding domain, such as a poly-histidine segment capable of binding to a divalent metal ion; an immunoglobulin binding domain, such as Protein A, Protein G, T cell, B cell, Fc receptor or complement protein antibody-binding domains; and/or a sugar binding domain such as 3-galactosidase or maltose binding protein. Particularly preferred protective proteins include a glutathione binding domain, such as the carboxyl terminal region of S . japonicum GST, or a metal binding domain, such as a poly-histidine segment. Particularly preferred nucleic acid sequences of the present invention that encode fusion proteins include nGST- nP30.1008 which encodes GST-P30.336; nGST-nP30.873 which encodes GST-P30.291; nGST-nP30.924 which encodes GST- P30.308; nGST-nP30.789 which encodes GST-P30.263; nGST- nP30.771 which encodes GST-P30.257; nGST-nP30.867SS which encodes GST-P30.289SS; nGST-nP30.924SS which encodes GST- P30.308SS; nGST-nP30.783SS which encodes GST-P30.261SS; and nGST-nP30.771SS which encodes GST-P30.257SS. The nGST- containing nucleic acid sequences are similar to the nucleic acid sequences depicted in Fig. 3 except that a nucleic acid segment encoding a S . japonicum GST glutathione binding domain has been inserted immediately upstream from the nucleic acid sequence encoding the specified T . gondii P30 antigen. Note that for nucleic acid sequences encoding secretable antigens, the nucleic acid sequence is enqineered such that the encoded protein comprises a glutathione binding domain inserted between the
signal segment and the specified T . gondii P30 antigen. As such, these nucleic acid sequences encode fusion proteins including GST joined to modified T . gondii P30 antigens. A detailed description of certain of such nucleic acid sequences is presented in the Examples section.
In accordance with the present invention, recombinant molecules for use in the production of protective compounds in eukaryotic cells can be either packaging-competent or packaging-defective. Such recombinant molecules can be produced using methods heretofore disclosed. Packaging- defective recombinant molecules typically have essentially no restrictions with respect to the size of heterologous nucleic acid sequences that can be incorporated. Furthermore, they do not lead to the production of infectious particles. Packaging-competent recombinant vectors, in contrast, can effect self-packaging into viruses, thereby resulting in infection of cells over multiple generations.
Packaging-competent and packaging-defective recombinant molecules for use in the production of protective compounds in eukaryotic cells contain, respectively, packaging-competent and packaging-defective alphavirus expression vectors as heretofore described. Such alphavirus expression vectors can include hybrid vectors as heretofore described. Nucleic acid sequences encoding protective compounds are preferably operatively linked to alphavirus subgenomic promoters as heretofore described. Preferred vectors and promoters are as
heretofore described, with Sindbis expression vectors including Sindbis subgenomic promoters being particularly preferred.
Preferred Sindbis virus expression vectors for use in producing protective compounds in eukaryotic cells include packaging-defective vectors SV1 and SV2, as well as packaging-competent vectors SV3 , SV4 , SV5 and SV6. SV1 and SV2 , depicted in Fig. 4, are described in detail above. SV3 and SV4 each contain all the genes encoding nonstructural Sindbis virus polypeptides, all the genes encoding structural Sindbis virus polypeptides under the control of a Sindbis subgenomic promoter, an additional subgenomic promoter to which a nucleic acid sequence encoding a protective compound can be operatively linked, and about 62 nucleotides at the 3' end of the Sindbis viral genome plus the poly(A) tail. In SV3, the gene order (5' to 3' ) is nonstructural polypeptide genes, structural polypeptide genes, nucleic acid sequence(s) encoding protective compound(s). In SV4, the gene order is nonstructural polypeptide genes, nucleic acid sequence(s) encoding protective compound(s) , structural polypeptide genes. SV5 is similar to SV3 except that a single subgenomic promoter controls expression of both the structural polypeptide genes and the nucleic acid sequence(s) encoding protective compound(s) . SV6 is similar to SV4 except that a single subgenomic promoter controls expression of both the nucleic acid sequence(s) encoding protective compound(ε) and structural polypeptide
genes. Sindbis expression vectors SV1, SV2, SV3 , SV4 , SV5 and SV6 each has a site for insertion of a nucleic acid sequence of the present invention, the site being flanked by Xj al and Xhol restriction endonuclease sites; see, for example, the depiction of SV1 and SV2 in Fig. 4. It can be appreciated, however, by one skilled in the art that such insertion sites can be flanked by a variety of restriction enzyme sites to allow easy insertion of nucleic acid sequences of the present invention into a variety of expression and cloning vectors.
A preferred recombinant molecule for use in producing protective compounds in eukaryotic cells in accordance with the present invention includes an alphavirus expression vector operatively linked to at least one preferred nucleic acid sequence of the present invention. Such a recombinant molecule can include one or more nucleic acid sequences operatively linked to one or more transcription control sequences (e.g., alphavirus subgenomic promoters). A more preferred recombinant molecule includes a Sindbis virus expression vector and at least one nucleic acid sequence operatively linked to a Sindbis virus subgenomic promoter, the nucleic acid sequence encoding a T. gondii P30 antigen, a D . immitiε P39 antigen, a D . immitiε P22L antigen, a D . immitiε P22U antigen, a D . immitiε P20.5 antigen, a D . immitis P4 antigen, a D . immitiε Di22 antigen (such as the Di22.RA antigen described in the Examples) and/or an L3 and/or L4 D . immitiε protease. Preferably, the antigen also includes a signal segment, such as a t-PA signal
segment, capable of promoting secretion of the antigen and/or a fusion segment, such as a glutathione binding domain or metal binding domain. Particularly preferred recombinant molecules of the present invention comprise recombinant molecules in which SV1, SV2 , SV3 , SV4 , SV5 or SV6 iε operatively linked to at leaεt one of the following nucleic acid sequences: nP30.1008, nP30.924, nP30.873, nP30.789, nP30.771, nP30.924SS, nP30.867SS, nP30.783SS, nP30.771SS, nGST-nP30.1008,- nGST-nP30.924 , nGST-nP30.873 , nGST-nP30.789, nGST-nP30.771, nGST-nP30.924SS, nGST- nP30.867SS, nGST-nP30.783SS, nGST-nP30.771SS and nDi22.RA. Even more preferred recombinant molecules include SV3:nGST- nP30.771, SV3:nGST-nP30.771SS and SV3:nDi22.RA.
One aspect of the present invention is the use of an alphavirus expresεion vector to produce a fusion protein comprising a fusion segment joined to a protein heterologous to that alphavirus (i.e., a protein not of the same species as the alphavirus expression vector) . The present inventors are not aware of any reports of the production of fusion proteins in alphavirus-based systems. Moreover, although production of GST-based fusion proteins containing GST fusion segments has been reported in E . coli , the inventors believe they are firεt to succesεfully produce a GST-based fusion protein in eukaryotic cells. As such, the present invention includeε a recombinant molecule including an alphaviruε expreεsion vector operatively linked to a nucleic acid sequence encoding a fusion protein, the fusion protein including a fusion segment
joined to a protein heterologous to the alphavirus. Aε heretofore diεcloεed, preferred fusion segmentε include glutathione binding domains, metal binding domains, immunoglobulin binding domains and sugar binding domains, with a glutathione binding domain or a poly-histidine segment being more preferred. Also preferred are proteins that include a signal segment capable of directing εecretion of the protein from the cell that produced it.
Another preferred embodiment of the present invention is a recombinant molecule including a nucleic acid sequence operatively linked to an alphavirus expresεion vector, the nucleic acid εequence encoding a Toxoplasma antigen and/or a Dirofilaria antigen that includes a signal segment capable of secreting the antigen from an animal cell transfected by the recombinant molecule. The antigen can further include a fusion segment as heretofore disclosed.
The present invention includes use of recombinant molecules of the present invention to produce compounds capable of protecting an animal from disease caused by a parasite and/or capable of detecting the presence of such a parasite. Protective compounds of the present invention can be produced by a method that includes (a) culturing an animal cell transfected with a recombinant molecule of the present invention to produce the compound; and (b) recovering the compound.
As heretofore stated, transfection includeε any meanε for introducing a nucleic acid sequence, expresεion vector, recombinant molecule, or packaging vector, into an animal
host cell, including, but not limited to transformation, electroporation, microinjection, lipofection, adsorption, and protoplast fusion. Preferred transfection techniqueε are lipofection and electroporation. Suitable host cells for producing protective compounds in culture include, but are not limited to, mammalian, insect, avian, reptilian and amphibian cellε. Preferred host cells include mammalian, insect, and avian cellε. More preferred host cells include Chinese hamεter ovary cellε, baby hamεter kidney cells and chicken embryonic fibroblasts. As used herein, tranεfection can also include infection of an animal host cell by a recombinant alphavirus containing a recombinant molecule of the present invention. A number of host cellε are suitable for infection since alphaviruses have such wide host ranges as heretofore discloεed.
The preεent invention includeε a recombinant cell capable of producing at least one compound capable of protecting an animal from disease caused by a parasite. A recombinant cell of the -present invention compriεeε an animal cell transfected with a recombinant molecule capable of directing expresεion of the compound, the recombinant molecule including at leaεt one nucleic acid εequence encoding the compound operatively linked to an alphavirus expression vector. Preferred recombinant cells of the present invention are capable of producing compounds capable of protecting animals from infection by preferred parasites aε heretofore disclosed. More preferred recombinant cells are capable of producing compounds
capable of protecting animals from Toxoplasma and/or Dirofilaria infection, such as cells capable of producing heretofore disclosed Toxoplasma and/or Dirofilaria antigens. Particularly preferred recombinant cells are animal cells transfected with recombinant molecules in which SV1, SV2, SV3 , SV4 , SV5 or SV6 is operatively linked to at least one of the following nucleic acid sequences: nP30.1008, nP30.924, nP30.873, nP30.789, nP30.771, nP30.924SS, nP30.867SS, nP30.783SS, nP30.771SS, nGST- nP30.1008, nGST-nP30.924, nGST-nP30.873 , nGST-nP30.789, nGST-nP30.771, nGST-nP30.924SS, nGST-nP30.867SS, nGST- nP30.783SS, nGST-nP30.771SS and nDi22.RA. Even more preferred recombinant cells are animal cells transfected with SV3:nGST-nP30.771, SV3 :nGST-nP30.771SS or SV3:nDi22.RA.
In order to produce protective compounds of the present invention, a recombinant cell, produced aε described above, is cultured in an effective medium, using techniques such as thoεe deεcribed in Xiong et al. , ibid . Aε uεed herein, an effective medium refers to any medium in which the transfected cells can produce protective compounds of the present invention. An effective medium is typically an aqueouε medium comprising asεimilable carbohydrate, nitrogen and phoεphate εources, as well as appropriate salts, minerals, metalε and other nutrients, such as vitamins, growth factors and other hormones. The medium may compriεe complex nutrients or may be a defined medium. Recombinant cells of the present invention can be
cultured in conventional fermentation bioreactorε, which include, but are not limited to, batch, fed-batch, cell recycle and continuous fermentors. Culturing can alεo be conducted in εhake flaεks, test tubes, microtiter disheε and petri plates. Culturing is carried out at a temperature, pH and oxygen content appropriate for the recombinant cell. Such culturing conditions are well within the expertise of one of ordinary skill in the art. Exampleε of preferred effective media and culturing conditions are included in the Examples εection.
Depending on whether expression results in a protective protein having or lacking a signal segment, the resultant protein may be secreted into the medium or remain within the recombinant cell. The phrase "recovering the protein" refers simply to collecting the whole fermentation medium (including cells) containing the protein and can, but need not, entail additional stepε of separation or purification. Protective compounds of the present invention can be purified using a variety of εtandard protein or RNA purification techniqueε, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresiε, hydrophobic interaction chromatography, gel filtration chromatography, reverεe phaεe chromatography, chromatofocuεing and differential εolubilization.
Iεolated protective compoundε of the present invention are preferably retrieved in "substantially pure" form. As used herein, "substantially pure" refers to a purity that
allows for the effective use of the compound as a therapeutic composition or diagnostic. A vaccine for animals, for example, should exhibit no substantial toxicity and should be capable of stimulating ' the production of antibodies in a vaccinated animal. Preferred isolated compounds of the present invention include protective proteins, with Toxoplasma and Dirofilaria antigens being more preferred. Particularly preferred isolated proteins include P30.336, P30.308, P30.291, P30.289, P30.263, P30.261, P30.257, GST-P30.336, GST- P30.308, GST-P30.291, GST-P30.289, GST-P30.263, GST- P30.261, GST-P30.257 and Di22.RA.
Protective compounds made in accordance with the present invention have a variety of uses including, but not limited to, use as vaccines and other therapeutic compounds, use as diagnostic agents and use as antigens in the production of polyclonal or monoclonal antibodies.
One embodiment of the present invention iε a therapeutic compoεition capable of protecting an animal from disease caused by a parasite when the composition is administered to the animal in an effective amount. Therapeutic compositions of the present invention are produced by a method including (a) culturing a recombinant cell of the present invention to produce a compound capable of protecting the animal from the disease, (b) recovering the compound, and (c) formulating a therapeutic composition therefrom. A therapeutic composition of the present invention can include one or more of the following
protective compoundε: (a) a protective protein of the preεent invention, (b) a protective RNA εpecies of the present invention and/or (c) an antibody raised against a protective compound of the present invention, as described in more detail below. A multivalent therapeutic composition containing multiple protective compoundε targeting multiple paraεiteε can be produced by combining one or more protective compoundε after production, by culturing more than one recombinant cell in a culturing reaction or by producing more than one protective compound in a recombinant cell by, for example, transfecting an animal cell with one or more recombinant molecules and/or by transfecting an animal cell with a recombinant molecule containing more than one nucleic acid sequence encoding one or more protective compounds of the present invention. Preferred therapeutic compositions include one or more of the preferred protective compounds heretofore diεcloεed targeted against one or more of the preferred parasites heretofore disclosed. Therapeutic compositionε of the preεent invention can be adminiεtered to any animal; preferably to mammals, insectε and birds; and more preferably to humans, pigs, εheep, dogs, cats, cattle, horseε, poultry, ferretε, and other pets and/or economic food animals. Particularly preferred animals to protect include humans, dogs and cats.
Therapeutic compositionε of the preεent invention can be formulated in an excipient that the animal to be treated can tolerate. Examples of such excipients include water,
saline, Ringer'ε εolution, dextroεe εolution, Hank's εolution, and other aqueouε phyεiologically balanced εalt solutions. Nonaqueous vehicles, such as fixed oilε, sesame oil, ethyl oleate, or triglycerides may alεo be used. Other uεeful formulationε include suspenεionε containing viεcosity enhancing agents, such as sodium carboxymethylcellulose, εorbitol, or dextran. Excipients can alεo contain minor amounts of additives, εuch aε εubεtances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservativeε include thimeroεal, m or o-creεol, formalin and benzyl alcohol. Standard formulationε will either be liquid injectables or solids which can be taken up in a suitable liquid as a εuεpension or solution for injection. Thus, in a non-liquid formulation, the excipient may comprise dextrose, human serum albumin, preservativeε, etc., to which εterile water or εaline could be added prior to adminiεtration. In one embodiment of the present invention, the therapeutic composition can also include an immunopotentiator, such as an adjuvant or a carrier. Suitable adjuvantε or carrierε include the adjuvantε and carrierε εuitable for adminiεtration of recombinant viruε particle vaccineε of the preεent invention.
In order to protect an animal from disease caused by a parasite, a therapeutic composition of the present invention is administered to the animal in an effective
manner εuch that the compoεition iε capable of protecting that animal from the targeted diεease. For example, an isolated protective protein of the present invention, when administered to an animal in an effective manner, is able to elicit (i.e., stimulate) an immune responεe, preferably including both a humoral and cellular reεponεe, that iε sufficient to protect the animal from disease. Similarly, an antibody of the present invention, when adminiεtered to an animal in an effective manner, iε adminiεtered in an amount εo aε to be present in the animal at a titer that is εufficient to protect the animal from disease, at least temporarily. Protective RNA species of the present invention can alεo be adminiεtered in an effective manner, thereby reducing expression of parasitic proteins in order to interfere with parasite development or to produce immunogenε capable of eliciting a protective immune reεponεe.
Therapeutic compositions of the present invention can be administered to animals prior to parasite infection in order to prevent infection and/or can be administered to animalε after parasite infection in order to treat diεeaεe caused by the parasite. For example, protective proteins and antibodies thereof can be used aε immunotherapeutic agents. Acceptable protocols to administer therapeutic compoεitionε in an effective manner include individual doεe size, number of doses, frequency of dose administration, and mode of administration. Determination of such
protocols can be readily accomplished by thoεe εkilled in the art. A suitable single dose iε a doεe that iε capable of protecting an animal from paraεitic infection or disease when administered one or more times over a suitable time period. For example, a preferred εingle doεe of a protective protein or antibody therapeutic compoεition is from about 1 microgram (μg) to about 10 milligrams (mg) of the therapeutic composition for an animal about the size of an average size dog. Booster vaccinations can be administered from about 2 weeks to several years after the original administration. Preferably booster vaccinations are adminiεtered when the immune reεponse of the animal becomeε inεufficient to protect the animal from paraεitic infection. A preferred adminiεtration εchedule iε one in which from about 10 μg to about 1 mg of the vaccine per kg body weight of the animal is administered from about one to about two times over a time period of from about 2 weeks to about 12 months. Modes of administration can include, but are not limited to, subcutaneous, intradermal, intravenous, nasal, oral, transdermal and intramuεcular routeε.
According to one embodiment, a protective RNA εpecieε of the preεent invention can also be administered to an animal in a fashion to enable expresεion of the nucleic acid εequence into a protective protein in the animal to be protected from parasitic disease. An RNA species can be
• delivered in a variety of methods including, but not limited to, direct injection (e.g., aε "naked" RNA molecules, such as is taught, for example in Wolff et al.,
1990, Science 247, 1465-1468), packaged in a viral coat to form a recombinant viruε, and packaged aε a recombinant cell vaccine. RNA εpecieε packaged in a viral coat can, for example, comprise packaging-defective or packaging- competent recombinant molecules. Recombinant viruε particle vaccineε of the preεent invention are exampleε of packaging-defective recombinant moleculeε packaged in viral coatε. An example of a packaging-competent recombinant molecule packaged in a viral coat is presented in the Exampleε. Therapeutic compositions packaged in a viral coat can be administered using methodε aε diεcloεed for the adminiεtration of recombinant viruε particle vaccineε of the preεent invention.
A recombinant cell vaccine of the present invention includes recombinant cells of the present invention that express at least one protective protein. Such recombinant cellε can be administered in a variety of ways known to those εkilled in the art, preferably at doεeε ranging from about 108 to about 1012 cellε per kilogram body weight. Administration protocols are similar to thoεe deεcribed herein for protein-baεed therapeutic compoundε. A preferred recombinant cell vaccine compriεeε a recombinant cell to which at leaεt one protective protein of the preεent invention iε attached due to the protective protein including a hook that preventε the protective protein from being εecreted from the cell after production.
The efficacy of a therapeutic compoεition of the present invention to protect an animal from disease caused
by a parasite can be tested in a variety of ways including, but not limited to, detection of protective antibodies (using, for example, protective proteins of the present invention), detection of cellular immunity within the treated animal, or challenge of the treated animal with the targeted parasite or antigens thereof to determine whether the treated animal is resiεtant to diseaεe. Such techniqueε are known to thoεe skilled in the art.
One preferred embodiment of the present invention iε a method to protect an animal from toxoplasmosis by administering to the animal an effective amount of a therapeutic composition produced by a method including (a) culturing an animal cell transfected with a recombinant molecule to produce a T . gondii P30 antigen, the recombinant molecule comprising at least one nucleic acid sequence encoding the antigen operatively linked to an alphavirus expression vector; (b) recovering the antigen; and (c) formulating a therapeutic composition therefrom that can be administered in an effective amount to protect the animal from toxoplasmosis. Preferably the antigen is a modified T . gondii P30 antigen lacking amino and/or carboxyl terminal hydrophobic residues, such as P30.336, P30.308, P30.291, P30.289, P30.263, P30.261, P30.257, GST- P30.336, GST-P30.308, GST-P30.291, GST-P30.289, GST- P30.263, GST-P30.261, GST-P30.257 or a combination thereof.
Another preferred embodiment of the present invention iε a method to protect an animal from heartworm by adminiεtering to the animal an effective amount of a
therapeutic composition produced by a method including (a) culturing an animal cell transfected with a recombinant molecule to produce a D . immitiε antigen, the recombinant molecule comprising at leaεt one nucleic acid sequence encoding the antigen operatively linked to an alphavirus expresεion vector; (b) recovering the antigen; and (c) formulating a therapeutic compoεition therefrom that can be administered in an effective amount to protect the animal from heartworm. Preferably the therapeutic compositionε containε at least one of the following proteins: D . immitiε P39, D . immitiε P22L, D . immitiε P22U, D . immitis P20.5, D . immitis P4, D . immitis Di22 and/or D . immitiε proteaseε expressed in L3 and/or L4 larvae, or a protein sharing εignificant homology with such D . immitiε proteins. Particularly preferred antigens to protect against heartworm included D . immitiε Di22.RA, P39, P22L and/or P20.5.
The present invention also includes antibodies capable of selectively binding to a protective compound of the present invention. Such antibodieε can be either polyclonal or monoclonal antibodies. Antibodies of the preεent invention include functional equivalents such aε antibody fragmentε and genetically-engineered antibodieε, including εingle chain antibodieε, that are capable of selectively binding to at least one of the epitopes of a protective compound of the preεent invention.
A preferred method to produce antibodieε of the present invention includes (a) administering to an animal
an effective amount of a protective compound of the present invention to elicit an immune response and (b) recovering the antibodies. Antibodieε raised against defined compounds can be advantageouε becauεe such antibodies are not substantially contaminated with antibodies againεt other εubstances that might otherwiεe cause interference in a diagnostic asεay or εide effectε if uεed in a therapeutic compoεition.
Antibodies of the present invention have a variety of potential uses that are within the scope of the present invention. For example, εuch antibodieε can be uεed (a) aε therapeutic compoεitionε to paεεively immunize an animal in order to protect the animal from paraεite diεease, (b) as reagents in assays to detect parasite infection, and/or (c) aε tools to recover desired parasite proteins from a mixture of proteins and other contaminantε. Furthermore, antibodieε of the present invention can be used to target cytotoxic agents to parasite in order to directly kill parasites expressing proteins selectively bound by the antibodieε. Targeting can be accompliεhed by conjugating (i.e. , stably joining) such antibodies to the cytotoxic agents.
It is alεo within the scope of the present invention to use protective compoundε of the preεent invention and antibodieε thereof aε diagnostic agents. One embodiment is a diagnostic assay capable of detecting infection by a paraεite, the aεεay including a paraεitic antigen produced by a method including (a) culturing a recombinant cell
containing a recombinant molecule of the preεent invention that encodes the antigen to produce the antigen, and (b) recovering the antigen. The asεay alεo includeε a meanε for detecting the binding of an antibody indicative of paraεite infection to the paraεite antigen. Preferably the assay containε Toxoplaεma and/or Dirofilaria antigenε capable of detecting toxoplasmosiε or heartworm, respectively. Another embodiment is a diagnostic assay that detects parasite antigens using antibodieε aε diεcloεed in the present invention. The present invention also includes methods to detect parasite diseases, such aε toxoplasmosis, in animals using such asεayε. For example, one can contact a bodily fluid of the animal with a T . gondii P30 antigen produced in accordance with the present invention (i.e., using an alphavirus expresεion εyεtem) and detect toxoplaεmoεiε by determining the ability of the antigen to form a εelective complex with antibodieε in the bodily fluid. Preferably the antigen is a modified T . gondii P30 antigen lacking amino and/or carboxyl terminal hydrophobic residueε, εuch aε P30.336, P30.308, P30.291, P30.289, P30.263, P30.261, P30.257, GST-P30.336, GST- P30.308, GST-P30.291, GST-P30.289, GST-P30.263, GST- P30.261, GST-P30.257 or a combination thereof.
The following experimental reεultε are provided for purposes of illustration and are not intended to limit the scope of the invention.
Exampleε
Example 1
Thiε example deεcribes the production of nucleic acid sequenceε encoding recombinant T . gondii P30 antigens. A. An approximately 1020 base pair DNA fragment, called nP30.1008, shown in Fig. 3, containing the entire coding region for the T . gondii P30 antigen (about 336 amino acids, asεuming that the tranεlation initiation εite is as shown in Table 1) and flanked by Smal and Xjbal restriction endonuclease sites immediately adjacent to the translation initiation (start) site and Xhol, Kpnl , and
Mlul reεtriction endonuclease sites immediately adjacent to the translation termination (stop) site was copied from a clone (Burg et al. , ibid . ) containing the P30 gene with natural flanking sequence using polymerase chain reaction
(PCR) amplification (Sambrook et al., iJ id.) . The specific primers used in the amplification reaction were:
Primer #1
5' CCCGGGTCTA GA ATG TCG GTT TCG CTG CAC CAC 3' Smal Xjbal 1st ATG at amino terminus of P30
Primer #2
5' ACGCGTGGTA CCTCGAG TCA CGC GAC ACA AGC T 3' Mlul Kpnl Xhol Translation Stop Site
The nucleic acid sequence nP30.1008 was recovered, restricted with Xjbal and Xhol, and inserted into plasmid pBluescript II (a cloning vector available from Stratagene, San Diego, CA) which had also been restricted with Xjbal and Xhol. The resulting vector, referred to as pB:nP30.1008, encodes T . gondii antigen P30.336.
B. A nucleic acid sequence encoding a functionally equivalent P30 antigen, lacking both amino and carboxyl terminal hydrophobic residues, was produced by the following method. A fragment of about 800 base pairs was copied by PCR amplification of a portion of bP:nP30.1008
(produced as described in Example IA) using the following primers:
Primer #3
5' GTCGACCCCG GGTCTAGACC ATG GCA TCG GAT CCC CC 3' Sail Smal Xbal Ncol
Translation Start Site
Primer #4
5' ACGCGTGGTA CCTCGAG TTA TGC TGA CCC TGC AGC CCC GGC Kpnl Xhol Translation Stop Site
The amplified nucleic acid sequence, denoted nP30.789, is shown in Fig. 3. nP30.789 encodes P30.263, a protective protein, the primary translation product of which is about 263 amino acids, spanning amino acid from about 46 through amino acid about 308, as numbered in the deduced amino acid sequence of Table 1. As such, about 45 amino acid residueε have been removed from the amino terminuε and about 28 amino acid reεidues have been removed from the carboxyl terminus of P30.336.
C. A nucleic acid sequence encoding a functionally equivalent P30 antigen, lacking amino terminal hydrophobic reεidues, is produced by the following method. A fragment of about 880 base pairs iε copied by PCR amplification of a portion of bP:nP30.1008 (produced aε deεcribed in Example IA) uεing primer #3 (described in Example IB) and primer #2
(described in Example IA) . The amplified nucleic acid sequence, called nP30.873, iε εhown in Fig. 3. nP30.873 encodeε P30.291, a protective protein, the primary translation production of which is about 291 amino acids, spanning amino acid from about 46 through amino acid about 336, aε numbered in the deduced amino acid sequence of Table 1. As such, about 45 amino acid residues are removed from the amino terminus of P30.336.
D. Another nucleic acid sequence encoding a functionally equivalent P30 antigen, lacking amino terminal hydrophobic residues, was produced by the following method.
A fragment of about 880 base pairs was copied by PCR amplification of a portion of bP:nP30.1008 (produced aε described in Example IA) using the following primers: Primer #5
5' GTCGACTCTA GACCCGGG ATG GCA TCG GAT CCC CC 3'
Smal Translation Start Site
Primer #6
5' ACGCGTGGTA CCGAATTC TCA CGC GAC ACA AGC T 3' .EcoRϊ Translation Stop Site
This amplified nP30.873 nucleic acid sequence is similar to the nP30.873 nucleic acid εequence shown in Fig. 3 except that this nucleic acid sequence is flanked by Smal and .EcoRI restriction siteε rather than by XJbal and Xhol restriction siteε.
E. A nucleic acid sequence encoding a functionally equivalent P30 antigen, lacking carboxyl terminal hydrophobic residues, is produced by the following method. A fragment of about 940 base pairs is copied by PCR
amplification from bP:nP30.1008 (produced aε described in Example IA) using primer #1 (described in Example IA) and primer #4 (described in Example IB) . The amplified nucleic acid sequence, called nP30.924, is shown in Fig. 3. nP30.924 encodes P30.308, a protective protein, the primary translation product of which is about 308 amino acids, spanning amino acid from about 1 through amino acid about 308, as numbered in the deduced amino acid sequence of Table 1. As such, about 28 amino acid residueε are removed from the carboxyl terminuε of P30.336.
F. A nucleic acid εequence encoding a functionally equivalent P30 antigen, lacking both amino and carboxyl terminal hydrophobic reεidues, but having a signal sequence in its primary translation product is produced in the following manner. A fragment of about 783 base pairs is produced by PCR amplification of a portion of bP:nP30.1008 (produced as described in Example IA) using primer #7 and primer #4 (described in Example IB). Primer #7, shown below, contains a nucleic acid signal segment encoding the first about 23 residueε of human t-PA joined to a nucleotide sequence encoding amino acid residues about 48 through about 54 of P30.336.
Primer #7
5' GTCGACCCCG GGTCTAGACC ATG GAT GCA ATG AAG AGA GGG Xbal Translation Start of t-PA
CTC TGC TGT GTG CTG CTA CTG TGT GGA GCA GTC TTC GTT
TCG CCC AGC TCG GAT CCC CCT CTT GTT GCC 3' P30 Sequences
The amplified nucleic acid sequence, called nP30.783SS, encodes P30.261SS, a protective protein, the primary translation product of which is about 283 amino acids. P30.261SS is capable of being secreted as a protein, which upon secretion from the cell is very similar to P30.263 except that P30.261SS begins at amino acid 48 of P30 as numbered in the deduced amino acid sequence of Table 1, whereaε P30.263 beginε at amino acid 46. Amino acid 48 iε thought to be the amino-terminal amino acid of the mature P30 protein (Burg et al., iJid.).
G. A nucleic acid sequence which encodes a fusion segment (i.e., glutathione S-transferase, or GST) joined to a T . gondii antigen lacking a majority of amino and carboxyl terminal hydrophobic sequences was produced in the following manner.
P30.5 COS1.1 DNA, a clone containing the entire T. gondii antigen gene (Burg et al., i id.) was digested with BamHI and PstI in order to obtain a BamHX/Pεtl fragment of about 771 base pairs which encodes P30 antigen containing amino acid residues spanning from about 49 through about 305, as numbered in the deduced amino acid sequence of Table 1. The BamHI/Pεtl fragment was inserted into plasmid pBluescript II (available from Stratagene, San Diego, CA) which had alεo been digeεted with BamHI and PstI. The resulting vector, referred to as pB:nP30.771, encodes T. gondii antigen P30.257. Vector pB:nP30.771 was digested with BamHI and .EcoRI to obtain a BamHI/£coRI fragment of about 773 base pairε that waε subsequently
inserted into the GST fusion vector pGEX-1 (Smith et al. , pp. 31-40, 1988, Gene , Vol. 67) which had also been digested with BamHI and .EcoRI. The resultant vector, denoted pGEX:nP30.771, contained the nP30.771 coding region immediately adjacent to and in the same reading frame aε the GST gene, the tranεcription of which was under the control of the tac promoter.
A nucleic acid sequence of about 703 base pairs containing the GST coding region joined to the nP30.771 coding region, called nGST-nP30.771, was produced by PCR amplification of a portion of the pGEX:nP30.771 vector using the primers shown below:
Primer #8
5' GTCGACCCCG GG TCTAGACC ATG TCC CCT ATA CTA GG 3' Xbal Translation Start Site
Primer #9
5' ACGCGTGGTA CCTCGAG TCA G TCA G TCA CGATG 3'
Xhol Translation Stop Sites
As indicated, primer #8 εpans the GST translation start site of pGEX-1, and primer #9 spans the three translation stop siteε in pGEX-1. The amplified nucleic acid εequence nGST-nP30.771 encodes a GST fusion protein in which GST iε joined to a P30 protein of about 257 amino acids, the P30 protein lacking the initial about 48 amino acids and the terminal about 31 amino acids of P30.336.
Additional nucleic acid sequences encoding GST-based fusion proteins either lacking a signal segment (e.g., nGST-nP30.1008, nGST-nP30.924, nGST-nP30.873 and nGST- nP30.789 and/or containing a t-PA signal segment (e.g.,
nGST-nP30.924SS, nGST-nP30.867SS, nGST-nP30.783SS and nGST- nP30.771SS can be produced using similar techniques.
Example 2
This example describes the production of certain recombinant molecules containing nucleic acid sequences encoding P30 antigens.
A. A recombinant molecule containing a nucleic acid sequence encoding a full-length T . gondii P30 antigen iε produced by the following method. Sindbis virus expression vector TRCAT62 (see Xiong et al. , ibid . ) is a double- stranded DNA expression vector which contains (a) the genes encoding nonstructural Sindbis virus polypeptideε nεPl, nsP2, nsP3, and nsP4, (b) the subgenomic promoter plus 14 nucleotides downstream from the subgenomic RNA initiation site which is ligated to a gene encoding chloramphenicol acetyltransferase (CAT), (c) 62 nucleotides at the 3' end of the Sindbis viral genome plus the poly(A) tail, and (d) a bacteriophage SP6 promoter immediately upstream of the Sindbis virus nonstructural genes. The gene encoding CAT is flanked by an Xbal reεtriction εite at its 5'end and an Xhol restriction site at its 3' end.
Double stranded DNA recombinant molecule dSV2:nP30.1008 is produced in the following manner. TRCAT62 is digeεted with the restriction enzymes Xbal and Xhol, thereby removing the CAT gene and forming dSV2 (see Fig. 4) . Nucleic acid sequence nP30.1008 (produced as described in Example IA and shown in Fig. 3) iε digested
with Xbal and Xhol and subsequently ligated into dSV2 to form DNA recombinant molecule dSV2:nP30.1008.
RNA recombinant molecule SV2:nP30.1008 is produced from dSV2:nP30.1008 by digesting dSV2:nP30.1008 DNA with restriction enzyme Mlul and incubating the digested DNA with bacteriophage SP6 RNA polymerase under conditions εimilar to thoεe described by Xiong et al. , ibid . , and Rice et al., J. Virology 61 , 3809-3819, 1987, in order to produce run-off tranεcriptε compriεing SV2:nP30.1008. Trace quantitieε of 3H-UTP (uridine triphoεphate) or α-32P- CTP (cytoεine triphoεphate) are included in the transcription reaction to permit quantitation (i.e., using DE81 filter paper, available from Whatman Inc. , Clifton, NJ) and gel analysis of the RNA transcripts. B. Recombinant molecule SV3 :nGST-nP30.771 was produced as follows. An expresεion vector containing nGST- nP30.771 was produced by (a) digesting nGST-nP30.771 (produced as described in Example 1G) with Xjbal and Xhol : b) inserting the Xba /Xhol fragment into expression vector Toto2Jl which had also been digested with Xjbal and Xhol , to form DNA expression vector dSV3:nGST-nP30.771; (c) digesting dSV3:nGST-nP30.771 with Mlul to form a linear molecule; and (d) transcribing the linear molecule using bacteriophage SP6 RNA polymerase as described in Example 2A to obtain RNA expression vector SV3:nGST-nP30.771. Note that Toto2Jl is a Sindbiε viruε expreεεion vector that containε the SP6 RNA polymeraεe promoter and the entire Sindbis virus genome through to the Nεil restriction site
at nucleotide 11452 (i.e., each of the nonstructural polypeptide genes, the subgenomic promoter, and each of the structural polypeptide genes) ligated to an Sspl (nucleotide position 7499)/SstI restriction fragment from TRCAT62 which contains the subgenomic promoter, 14 nucleotides of the 5' untranslated sequence of the subgenomic mRNA, the CAT gene, 62 nucleotides of Sindbis virus 3' untranslated sequence, and the Sindbis virus poly- A εequence. C. A number of other RNA recombinant molecules can be produced as described above, including other recombinant molecules comprising SV1, SV2, SV3, SV4, SV5 or SV6 operatively linked to at least one of the following nucleic acid sequences: nP30.1008, nP30.924, nP30.873, nP30.789, nP30.771, nP30.924SS, nP30.867SS, nP30.783SS, nP30.771SS, nGST-nP30.1008, nGST-nP30.924, nGST-nP30.873, nGST- nP30.789, nGST-nP30.771, nGST-nP30.924SS, nGST-nP30.867SS, nGST-nP30.783SS and nGST-nP30.771SS.
Example 3 This Example describes a method to produce a Sindbis viruε packaging vector of the present invention. The example provided herein comprises a packaging vector containing the genetic information to encode Sindbis virus structural polypeptides and control signals for replication and transcription but not containing the site located within the nsPl gene thought to be required for packaging.
Therefore, the packaging vector cannot effect self- packaging.
A full-length cDNA copy of Sindbis virus vector TotolOOO (Rice et al. , ibid. ) is subjected to partial digestion by the restriction endonuclease Sεpl , which has cleavage sites at about nucleotideε 504, 4130, 7499, and 11954. The desired Sspl restriction fragment, which includes a span of nucleotides from about nucleotide 7499 through about nucleotide 504, including nucleotide "0" as indicated in Fig. 5, iε iεolated, uεing low melt agaroεe gel chromatography and elution techniques as deεcribed in Sambrook et al., ibid . The deεired fragment is then self- ligated using standard ligation technology. The reεultant vector, which represents the DNA copy of the packaging vector and is referred to as dPVl, contains the subgenomic promoter, all of the Sindbis virus structural genes, replication and transcription signals at the 5' and 3' ends of the linear viral RNA genome, and a bacteriophage SP6 promoter but does not contain the site thought to be required for packaging in the nsPl gene or geneε that encode functional nsPl, nsP2, nsP3 , or nsP4 polypeptides. Thus, the packaging vector can work as a "helper" to provide structural polypeptides "in tranε" to enable packaging of recombinant molecules of the present invention.
RNA packaging vector PV1 is produced in a manner similar to the RNA recombinant molecules described in Example 2. Briefly, dPVl is digested with restriction
enzyme Sεtl , and the linearized DNA iε incubated with bacteriophage SP6 RNA polymerase. The reεultant RNA iε referred to PV1.
Example 4 Thiε Example describes the production of a recombinant viruε particle vaccine of the present invention.
A recombinant viruε particle vaccine iε produced by co-tranεfecting a host cell with a recombinant molecule and an alphavirus packaging vector, culturing the host cell in an effective medium to produce the vaccine, and recovering the vaccine.
In one experiment, recombinant virus particle vaccine VPV SV2:nP30.1008 is produced by co-transfecting baby hamster kidney (BHK) cellε with recombinant molecule SV2:nP30.1008 and packaging vector PV1 uεing electroporation in a manner similar to that described by Liljestrom et al. , ibid . Briefly, BHK cells are grown in 60 mm tiεεue culture plateε to a monolayer confluency of about 90%. The cellε are trypsinized, washed once with Minimal Essential Medium (also called MEM; available from Life Technologies Inc., Gaitherεburg, MD) containing 10% fetal calf serum, washed once with ice cold phoεphate buffered saline (8 g NaCl, 0.2 g KC1, 1.44 g Na2HP04, 0.24 g KH2P04 per liter of water, the pH of which iε adjuεted to about pH 7.4; alεo called PBS) and reεuεpended in PBS at about 1 x 107 cells per ml. About 0.5 ml of cells and about 5-10 μg (in about 10-50 microliters (μl) ) total of
SV2 :nP30.1008 and PV1 (at a mole/mole ratio of about 1:1) are mixed in a 0.2 centimeter (cm) cuvette suitable for use in Bio-Rad's Gene Pulser Apparatus (both available from Bio-Rad Laboratories, Richmond, CA) . The RNA either may be used directly from the in vitro transcription reaction mixture (aε deεcribed in Example 2 for the recombinant molecule and in Example 3 for the packaging vector) or may be diluted with tranεcription buffer containing 5 millimolar (mM) dithiothreitol and 1 unit of RNasin per ml. Electroporation is conducted at room temperature by two consecutive pulseε at 1.5 kilovoltε (KV) and 35 microfaradε (μF) , using the Gene Pulser Apparatus with the pulse controller unit set at maximum resiεtance. After electroporation, the cellε are diluted about 1:20 in complete BHK cell medium and transferred to tissue culture plates. The cells are then cultured for about 24 to about 36 hourε at about 37°C and about 5% carbon dioxide in about 5 ml of MEM with 10% fetal calf εerum.
Plaque forming units (pfu) are quantified by overlaying the monolayerε of BHK cellε with 2 ml of 1.2% Seakem agaroεe (available from FMC Corp. , Marine Colloidε Div., Rockland, ME) diluted 1:1 (vol/vol) in MEM and 2% fetal calf εerum, incubating at about 37°C for about 24 to about 48 hourε, and εtaining with neutral red or cryεtal violet.
VPV SV2:nP30.1008 iε recovered from the culture uεing Matrex® Cellufine™ Sulfate Media & Virus Recovery System, available from Amicon Inc., Danvers, MA.
Example 5
This Example describeε the effect of adminiεtering a recombinant viruε particle vaccine of the present invention to mice. Recombinant virus particle vaccine VPV SV2:nP30.1008, produced as described in Example 4, iε injected into CD-I mice using the following protocol. The vaccine iε mixed with Hankε' Balanced Salt Solution (HBSS; available from
Life Technologies Inc., Gaithersburg, MD) to give a vaccine formulation of about 1 x 105 pfu of VPV SV2:nP30.1008 per ml formulation. Each mouse is injected subcutaneously with approximately 0.1 ml of the vaccine formulation at day 0 and at about days 21 to 28. Control CD-I mice are administered an equivalent amount of native Sindbis virus in HBSS.
The ability of the mice to produce antibodies against T . gondii parasiteε iε meaεured using an enzyme-linked immunoasεay (ELISA) . Purified εonicated parasiteε are placed in microtiter plateε and blocked with 5% Fetal Bovine Serum (FBS) . Sera collected from mice are incubated for 2 hr at 37"C in the paraεite-coated microtiter wellε and washed with PBS containing 0.4 % of the nonionic detergent Tween 20. Anti-T. gondii antibodies present in the εerum are identified uεing peroxidase-labeled goat anti-mouse IgG antibodies (available from Cappell Laboratories, Cochranville, PA) in a standard ELISA.
The ability of VPV SV2:nP30.1008 to protect the mice from T . gondii infection is determined as followε.
Immunized mice are challenged intraperitoneally with about 5 x 105 T . gondii C strain tachyzoites per mouεe. Mice are monitored twice a day until signs of lethal toxoplasmosiε are evident at which time the mice are euthanized with an overdoεe of metaphane. After 30 days post challenge, all surviving mice are euthanized with an overdose of metaphane and the number of brain cystε determined by removing the brainε from the animals, gently homogenizing the brain tiεsue in PBS, and counting cysts in 10-μl sampleε in a hemacytometer. CD-I mice vaccinated with VPV SV2:nP30.1008 show few if any brain cystε upon infection by T . gondii , especially as compared to mice vaccinated with Sindbis virus.
Thus, VPV SV2:nP30.1008 is capable of protecting mice from T. gondii infection. Mice are a suitable model for T . gondii infection studies since the chronology and outcome of infection in most warm-blooded animals is very similar.
Example 6
This Example describeε the production of a recombinant cell capable of expreεsing a modified P30 antigen and use of the recombinant cell to produce an antigen capable of eliciting an immune response against T . gondii and antigens thereof.
The ability of GST-P30.257, the fusion protein encoded by nucleic acid sequence nGST-nP30.771, to elicit an immune response againεt toxoplaεma infection waε determined aε follows.
A recombinant cell capable of expreεεing the GST- P30.257 fuεion protein waε produced by tranεfecting SV3:nGST-nP30.771 into baby hamster kidney (BHK) cells using electroporation in a manner similar to that deεcribed by Liljeεtrom et al. , ibid . Briefly, BHK cellε were grown in 60 mm tissue culture plates to a monolayer confluency of about 90%. The cellε were trypεinized, waεhed once with Minimal Eεεential Medium (alεo called MEM; available from Life Technologieε Inc. , Gaitherεburg, MD) containing 10% fetal calf εerum, waεhed once with ice cold phoεphate buffered εaline (8 g NaCl, 0.2 g KC1, 1.44 g Na2HP04, 0.24 g KH2P04 per liter of water, the pH of which is adjusted to about pH 7.4; also called PBS) and resuεpended in PBS at about 1 x 107 cellε per ml. About 0.5 ml of cellε and about 5-10 μg (in about 10-50 μl) of SV3:nGST-nP30.771 were mixed in a 0.2 centimeter (cm) cuvette suitable for use in Bio-Rad's Gene Pulεer Apparatuε (both available from Bio¬ Rad Laboratories, Richmond, CA) . The RNA was either used directly from the in vitro tranεcription reaction mixture (aε described in Example 2) or was diluted with transcription buffer containing 5 illimolar (itiM) dithiothreitol and 1 unit of RNasin per ml. Electroporation was conducted at room temperature by two consecutive pulseε at 1.5 kilovoltε (KV) and 35 microfaradε (μF) , uεing the Gene Pulεer Apparatus with the pulse controller unit set at maximum resistance. After electroporation, the cells were diluted about 1:20 in
complete BHK cell medium and tranεferred to tiεsue culture plates.
Transfected cells were then cultured in MEM medium with 10% fetal calf serum for about 24 to about 36 hours at about 37°C in order to produce GST-P30 recombinant viruε. BHK cellε were infected by GST-P30 recombinant viruε and incubated for about 12 to about 16 hourε at 37°C to produce GST-P30.257. The GST-P30.257 that waε expreεεed from SV3:nGST-nP30.771 waε specifically recognized by (i.e., selectively bound with high affinity to) polyvalent antiserum produced against native T. gondii P30 protein, polyvalent antiserum produced against T. gondii tachyzoite cell lysate, and P30 monoclonal antibodieε 1G5 and 5D12 in immunoblot analyεiε experimentε. Rabbit polyvalent antiεera produced against native P30 protein or against tachyzoite cell lysates were obtained from L. H. Kasper, Department of Medicine and Microbiology, Section of Neurology, Dartmouth Medical School, Hanover, NH. P30 monoclonal antibodies 1G5 and 5D12 were obtained from J. S. Remington, Department of Immunology and Infectiouε
Diseaseε, Reεearch Inεtitute, Palo Alto Medical Foundation,
Palo Alto, CA. ELISA protocols are discuεεed in Example 5.
GST-P30.257 waε purified by glutathione εepharose 4B chromatography (resin available from Pharmacia Biotech Inc. , Piεcataway, NJ) uεing a technique εimilar to that deεcribed by Smith et al., ibid . The purified protein waε uεed to immunize a rabbit according to the following protocol. About 40 μg of GST-P30.257 waε injected into a
rabbit on days 0, 21, and 42. Serum was collected from the rabbit at day 56 and found to react with (i.e., bind to) both native T . gondii P30 antigen and T . gondii tachyzoite parasiteε in an immunoblot aεεay, indicating that GST- P30.257 was capable of eliciting an immune responεe against toxoplasma infection.
Example 7
This Example demonstrateε the ability of a modified T . gondii P30 antigen to protect an animal from toxoplaεmosis. Protective protein GΞT-P30.257, produced aε deεcribed in Example 6, iε injected into CD-I mice uεing the following protocol. GST-P30.257 iε formulated with an adjuvant (e.g., Freund'ε complete adjuvant, Freund's incomplete adjuvant, liposomeε or Quil A) , uεing standard formulation protocols, to produce a therapeutic composition. Each mouse iε injected εubcutaneouεly with approximately 0.1 ml of the therapeutic compoεition (including about 10 μg of GST-P30.257) at day 0 and at about day 14. Negative control CD-I mice are adminiεtered adjuvant alone and/or with GST, whereaε poεitive control mice are administered native T . gondii P30 antigen formulated with liposomes, which haε been εhown by Bulow et al., ibid . , to protect mice from Toxoplasma infection.
The ability of the mice to produce antibodieε against T. gondii parasiteε iε meaεured uεing an enzyme-linked immunoassay (ELISA) . Purified sonicated parasiteε are placed in microtiter plateε and blocked with 5% Fetal
Bovine Serum (FBS) . Sera collected from mice are incubated for 2 hr at 37"C in the paraεite-coated microtiter wellε and washed with PBS containing 0.4 % of the nonionic detergent Tween 20. Anti-T. gondii antibodies present in the serum are identified using peroxidase-labeled goat anti-mouse IgG antibodies (available from Cappell Laboratories, Cochranville, PA) in a standard ELISA.
The ability of GST-P30.257 to protect the mice from T . gondii infection is determined as follows. GST-P30.257 immunized mice are challenged intraperitoneally with about 5 x 105 T . gondii C strain tachyzoites per mouse. Mice are monitored twice a day until signε of lethal toxoplaεmoεiε are evident at which time the mice are euthanized with an overdose of metaphane. After 30 days post challenge, all surviving mice are euthanized with an overdose of metaphane and the number of brain cysts determined by removing the brains from the animals, gently homogenizing the brain tiεεue in PBS, and counting cyεtε in 10-μl samples in a hemacytometer. CD-I mice vaccinated with GST-P30.257 plus adjuvant εhow few if any brain cysts upon infection by T . gondii , especially as compared to mice vaccinated with adjuvant alone.
Thus, GST-P30.257 is capable of protecting mice from T . gondii infection. Mice are a suitable model for T . gondii infection εtudieε εince the chronology and outcome of T . gondii infection in most warm-blooded animals is similar.
Example 8
This Example describeε the production of nucleic acid εequenceε encoding recombinant D . immitis Di22 antigenε.
A nucleic acid sequence encoding a D . immitiε -Di22 antigen (included in GeneBank data baεe acceεεion number
M82811) containε a nucleotide repeat of 399 base pairs that encodeε a peptide of 133 amino acidε, referred to aε
Di22.RA. A nucleic acid sequence encoding Di22.RA flanked by an Xhal restriction endonuclease site adjacent to the translation initiation (start) site and an Xhol restriction endonuclease site adjacent to the translation termination
(stop) site was copied from the Di22 nucleic acid sequence using PCR amplification. The specific primers used in the amplification reaction were: Primer #10
5' GTCGACCCCG GGTCTAGAAC C ATG GCT CTC AGT GAA ATC A 3'
Xbaτ 1st ATG at amino terminus of RA
Primer #11
5' ACGCGTGGTA CCTCGAG TCA TCT GCA GCC TTC TTG AA 3' Xhol Translation Stop Site
The reεultant nucleic acid εequence, referred to aε nDi22.RA, waε recovered, restricted with Xbal and Xhol, and inserted into plaεmid pBluescript II, which had also been restricted with Xbal and Xhol. The resulting vector, referred to as pB:nDi22.RA, encodes the D . immitis antigen Di22.RA.
Example 9
This Example describes the production of a recombinant molecule containing a nucleic acid sequence encoding a D . immitis Di22 antigen. Recombinant molecule SV3:nDi22.RA was produced by (a) digesting pB:nDi22.RA (described in Example 8) with Xbal and Xhol ; (b) inserting the nDi22.RA Xbal/Xhol fragment into expression vector Toto2Jl (described in Example 2B) which had also been digested with Xbal and Xhol, to form DNA expreεεion vector dSV3 :nDi22.RA; (c) digeεting dSV3 :nDi22.RA with Mlul to form a linear molecule; and (d) tranεcribing the linear molecule uεing bacteriophage SP6 RNA polymeraεe as described in Example 2A to obtain RNA expresεion vector SV3:nDi22.RA.
Example 10
Thiε Example describes the production of a recombinant cell capable of expressing a D . immitiε Di22 antigen and use of the recombinant cell to produce an antigen capable of selectively binding to antisera raiεed againεt a D . immitis Di22 antigen expressed in E . coli aε well as to dog immune serum capable of inhibiting heartworm development; preparation of εuch dog immune εerum iε diεcloεed in Grieve et al. , ibid .
A recombinant cell capable of expreεsing Di22.RA waε produced by transfecting SV3:nDi22.RA into BHK cells using lipofection in a manner similar to that deεcribed by Feigner et al. , pp. 7413-7417, 1987, Proc . Natl . Acad . Sci .
USA, Vol. 84. Briefly, BHK cells were grown in 60 mm tisεue culture plateε to a monolayer confluency of about 90%. The cellε were washed with PBS and incubated for about 10 minutes at about room temperature with a mixture of from about 0.25 to about 1.0 μg of SV3:nDi22.RA and about 20 μg of Lipofectin (available from Life Technologieε Inc., Gaithersburg, MD) in about 0.4 ml PBS. The mixtures was then removed and the cells washed two times with PBS and incubated with about 5 ml of MEM containing 10% fetal calf serum for about 24 to about 36 hours at about 37°C in order to produce recombinant virus. BHK cellε were infected by the recombinant viruε and incubated for about 12 to about 16 hours at about 37°C to produce Di22.RA.
Recombinant cellε were lysed, and the resultant lysateε were fractionated by SDS-PAGE, tranεferred to nitrocelluloεe paper and incubated either with the immune dog εerum referred to above or with rabbit antiserum raised to a Di22 antigen produced by E . coli using standard techniques. Immunoblot analyεis of experiments using either serum indicated the presence of a protein of about 15 kD (corresponding to the about 133 amino acid Di22.RA polypeptide) in lysateε from cellε expressing Di22.RA but not in lysates from cellε infected with wild-type Sindbis virus or in lyεateε from non-infected cellε. These results indicate that SV3:nDi22.RA can direct the production of a D . immitiε antigen recognized by serum capable of inhibiting heartworm development as well as by antibodieε raised against recombinant Di22 produced by bacteria.
Example 11
Thiε Example deεcribeε the production of a therapeutic compoεition compriεing a packaging-competent recombinant molecule capable of expreεεing a heartworm antigen packaged in a viral coat. Thiε Example also demonstrates the ability of such a therapeutic composition to slow the growth of heartworm larvae.
Packaging-competent recombinant molecule SV3:nDi22.RA, produced as described in Example 9, was packaged into a viral coat as follows. SV3:nDi22.RA was transfected into BHK cells using lipofection in a manner similar to that described by Feigner et al. , pp. 7413-7417, 1987, Proc . Natl . Acad . Sci . U .S .A. , Vol. 84. Briefly, BHK cells were grown in 60 mm tissue culture plates to a monolayer confluency of about 90%. The cells were washed with PBS and incubated for about 10 minutes at about room temperature with a mixture of from about 0.25 to about 1.0 μg of SV3:nDi22.RA and about 20 μg of Lipofectin (available from Life Technologies Inc., Gaithersburg, MD) in about 0.4 ml PBS. The mixtures was then removed and the cells washed two times with PBS and incubated with about 5 ml of MEM containing 10% fetal calf serum for about 24 to about 36 hours at about 37°C in order to produce recombinant virus RV SV3 :nDi22.RA, also known as HJA. Female C57 BL/6J mice, about 6 to 8 weekε old, were inoculated subcutaneously in the inguinal region as follows:
(a) 8 mice were each inoculated with about 5 x 106 pfu of RV SV3:nDi22.RA in about 0.1 ml of Hanks' Balanced Salt Solution with 1 percent fetal calf εerum (HBSS/1% FCS) ;
(b) 8 mice were each inoculated with about 5 x 106 pfu of non-recombinant Sindbiε viruε in about 0.1 ml HBSS/1%
FCS; and
(c) 6 mice were each inoculated with 0.1 ml HBSS/1% FCS.
About 14 days after the initial injection, each mice was boosted with the same dose of the same material as was initially injected. About 35 days after the initial injection, each mouse waε implanted with a diffusion chamber containing about 40 D. immitiε L3 larvae, according to the technique described by Abraham et al., 1988, J . Paraεitol . 74 , 275-282. (One mouse administered the recombinant virus died.) The chambers were removed about
56 days after the initial injection and analyzed for larval survival and growth as described in Abraham et al. , ibid .
About 65% of the larvae were recovered from chambers implanted on mice administered the recombinant virus RV SV3:nDi22.RA in HBSS/1% FCS (RV larvae), of which about 38% had died. About 61% of the larvae were recovered from chambers implanted on mice administered the non-recombinant Sindbiε viruε in HBSS/1% FCS (SV larvae) , of which about 22% had died. About 72% of the larvae were recovered from
' chambers implanted on mice administered HBSS/1% FCS along
(HBSS larvae) , of which about 16% had died. Living RV larvae exhibited significantly stunted growth compared to
living SV larvae and living HBSS larvae. That iε, living RV larvae exhibited an average length of 370.653 ± 29.249 μm (micrometers) compared to living SV larvae which exhibited an average length of 387.769 ± 39.793 μm (p = 0.0045), and to living HBSS larvae which exhibited an average length of 382.321 ± 41.837 μm (p = 0.0396) . These results indicate that adminiεtration of RV SV3:nDi22.RA can lead to the production of a D . immitiε antigen capable of εtunting larval heartworm growth.
While various embodiments of the present invention have been deεcribed in detail, it iε apparent that modificationε and adaptationε of thoεe embodimentε will occur to thoεe εkilled in the art. It iε to be expreεεly underεtood, however, that such modificationε and adaptations are within the scope of the present invention, as set forth in the following claimε:
Claims (77)
1. A recombinant virus particle vaccine comprising a packaging-defective recombinant molecule packaged in an alphavirus coat, said packaging-defective recombinant molecule comprising a nucleic acid sequence that encodes at leaεt one protective compound εelected from the group consisting of protective proteins and protective RNA specieε, εaid nucleic acid εequence being operatively linked to a packaging-defective alphaviruε expreεεion vector that iε capable of directing expreεεion of said packaging-defective recombinant molecule.
2. The vaccine of Claim 1, wherein said packaging- defective alphavirus expresεion vector is capable of directing replication of said packaging-defective recombinant molecule.
3. The vaccine of Claim 1, wherein an animal having εaid vaccine adminiεtered thereto produceε εaid protective compound.
4. The vaccine of Claim 1, wherein εaid disease is caused by an infectious agent selected from the group conεiεting of protozoan paraεites, helminth parasites, ectoparasites, fungi, bacteria, and viruseε.
5. The vaccine of Claim 1, wherein εaid diεeaεe iε caused by an infectiouε agent εelected from the group conεisting of the genera Toxoplasma , Dirofilaria , Acanthocheilonema , Babesia , Brugia , Candida , Cryptococcuε , Cryptosporidium , Dipetalonema , Eimeria , Encephalitozoon , Hepatozoon , Histoplaεma , Iεoεpora , Loa , Microεporidia , Neoεpora , Noεema , Onchocerca , Parafilaria , Plaεmodium , Pneumocyεtiε , Rochalimaea , Setaria , Stephanofilaria, Theileria and Wuchereria .
6. The vaccine of Claim 1, wherein said animal iε εelected from the group conεiεting of mammalε, inεectε, and birds.
7. The vaccine of Claim 1, wherein said protective compound iε capable of eliciting an immune response to protect εaid animal from said disease.
8. The vaccine of Claim 1, wherein εaid protective compound compriεeε a Toxoplaεma gondii antigen capable of eliciting an immune reεponse to protect said animal from toxoplaεmoεis.
9. The vaccine of Claim 1, wherein said protective compound comprises a Toxoplaεma gondii P30 antigen capable of eliciting an immune response to protect said animal from toxoplasmosiε.
10. The vaccine of Claim 1, wherein said protective compound compriseε a Toxoplaεma gondii P30 antigen εelected from the group consisting of P30.336, P30.308, P30.291, P30.289, P30.263, P30.261, and P30.257.
11. The vaccine of Claim 1, wherein said nucleic acid sequence encodes a protective protein further comprising a signal segment capable of promoting secretion of said protective protein.
12. The vaccine of Claim 1, wherein said packaging- defective alphavirus expression vector is selected from the group consiεting of packaging-defective Sindbis virus expression vectors, packaging-defective Semliki Forest virus expression vectors, packaging-defective Roεε River virus expresεion vectorε, packaging-defective Venezuela equine encephalitiε viruε expression vectors, or wherein said packaging-defective alphavirus expression vector co priseε a hybrid of any one or more of εaid packaging- defective alphaviruε expression vectorε.
13. The vaccine of Claim 1, wherein said packaging- defective alphavirus expression vector further comprises an alphavirus subgenomic promoter operatively linked to said nucleic acid εequence.
14. The vaccine of Claim 1, wherein εaid packaging- defective recombinant molecule iε produced by a method compriεing operatively linking a nucleic acid εequence encoding a protective compound to a packaging-defective alphaviruε expreεεion vector capable of directing expreεεion of εaid packaging-defective recombinant molecule to obtain a packaging-defective recombinant molecule.
15. The vaccine of Claim 1, wherein εaid packaging- defective recombinant molecule iε εelected from the group conεisting of SVl:nP30.1008, SVl:nP30.924 , SVl:nP30.873 , SVl:nP30.789, SV1:nP30.771, SV1:nP30.924SS, SV1:nP30.867SS, SV1 : nP30.783SS , SV1 : nP30.771SS , ΞV2 : nP30.1008 , SV2:nP30.924, SV2:nP30.873 , SV2 :nP30.789, SV2:nP30.771, SV2:nP30.924SS, SV2:nP30.867SS, SV2:nP30.783SS, and SV2:nP30.771SS.
16. The vaccine of Claim 1, wherein said vaccine is produced by a method comprising: (a) co-transfecting a host cell with εaid packaging-defective recombinant molecule and an alphavirus packaging vector, said packaging vector being able to effect packaging of said packaging-defective recombinant molecule into a recombinant virus particle comprising εaid packaging-defective recombinant molecule packaged into an alphavirus coat, said packaging vector being eεεentially incapable of self-packaging;
(b) culturing said transfected cell in an effective medium to produce said recombinant viruε particle;
(c) recovering said recombinant virus particle; and
(d) formulating a vaccine therefrom.
17. The vaccine of Claim 16, wherein εaid packaging vector compriεeε PV1.
18. The vaccine of Claim 1, wherein said vaccine iε produced by a method compriεing:
(a) transfecting a host cell with said packaging-defective recombinant molecule, said host cell being capable of packaging said packaging-defective recombinant molecule into a recombinant virus particle comprising said packaging-defective recombinant molecule packaged into an alphavirus coat; (b) culturing said transfected cell in an effective medium to produce said recombinant virus particle; (c) recovering εaid recombinant viruε particle; and
(d) formulating a vaccine therefrom.
19. The vaccine of Claim 1, wherein εaid nucleic acid sequence is εelected from the group conεisting of nP30.1008, nP30.924, nP30.873, nP30.789, nP30.771, nP30.924SS, nP30.867SS, nP30.783SS and nP30.771SS.
20. The vaccine of Claim 1, wherein εaid vaccine iε εelected from the group consiεting of VPV SVl:nP30.1008, VPV SVl:nP30.924, VPV SVl:nP30.873, VPV SVl:nP30.789, VPV SVl:nP30.771, VPV SVl:nP30.924SS, VPV SV1:nP30.867SS, VPV SVl:nP30.783SS, VPV SV1:nP30.771SS, VPV SV2:nP30.1008, VPV SV2:nP30.924, VPV SV2:nP30.873, VPV SV2:nP30.789, VPV SV2:nP30.771, VPV SV2:nP30.924SS, VPV SV2:nP30.867SS, VPV SV2:nP30.783SS, and VPV SV2:nP30.771SS.
21. The vaccine of Claim 1, further comprising a therapeutic composition comprising said protective compound.
22. An iεolated nucleic acid sequence encoding a modified Toxoplaεma gondii P30 antigen εelected from the group consisting of a P30 antigen lacking amino terminal hydrophobic residueε, a P30 antigen lacking carboxyl terminal hydrophobic reεidueε, and a P30 antigen lacking both amino terminal and carboxyl terminal hydrophobic reεidueε.
23. The nucleic acid sequence of Claim 22, wherein said nucleic acid encodes a modified antigen further compriεing a εignal segment, a fusion segment, or a combination thereof.
24. The nucleic acid sequence of Claim 22, wherein said nucleic acid sequence is selected from the group consiεting of nP30.924, nP30.873, nP30.789, nP30.771, nP30.924SS, nP30.867SS, nP30.783SS, nP30.771SS.
25. A modified T . gondii P30 antigen εelected from the group conεiεting of a P30 antigen lacking amino terminal hydrophobic reεidueε, a P30 antigen lacking carboxyl terminal hydrophobic reεidueε, and a P30 antigen lacking both amino terminal and carboxyl terminal hydrophobic reεidueε.
26. The modified antigen of Claim 25, wherein said modified antigen is capable of protecting an animal from toxoplasmoεiε when εaid antigen iε adminiεtered to εaid animal in an effective amount.
27. The modified antigen of Claim 25, wherein said modified antigen is capable of diagnosing infection by T. gondii .
28. The modified antigen of Claim 25, wherein said modified antigen compriseε a εignal εegment, a fuεion εegment, or a combination thereof.
29. The modified antigen of Claim 25, wherein said modified antigen iε εelected from the group conεiεting of P30.336, P30.308, P30.291, P30.289, P30.263, P30.261, P30.257, GST-P30.336, GST-P30.308, GST-P30.291, GST-
P30.289, GST-P30.263, GST-P30.261 and GST-P30.257.
30. A packaging vector comprising PV1.
31. A method to protect an animal from diεeaεe, compriεing adminiεtering to εaid animal an effective amount of a recombinant virus particle vaccine having a packaging- defective recombinant molecule packaged in an alphavirus coat, said packaging-defective recombinant molecule comprising a nucleic acid sequence that encodes at least one protective compound, εaid nucleic acid εequence being operatively linked to a packaging-defective alphavirus expression vector capable of directing expression of said packaging-defective recombinant molecule, said animal being capable of expreεεing εaid packaging-defective recombinant molecule.
32. The method of Claim 31, wherein εaid disease iε cauεed by an infectiouε agent εelected from the group conεisting of protozoan parasites, helminth parasiteε, ectoparasites, fungi, bacteria, and viruses.
33. The method of Claim 31, wherein εaid animal iε εelected from the group conεiεting of mammals, inεectε, and birdε.
34. The method of Claim 31, wherein said sequence encodes a protective compound comprising a Toxoplaεma gondii P30 antigen.
35. The method of Claim 31, further comprising adminiεtering to εaid animal a substantially pure protective compound prior to, following, or both prior to and following administering said recombinant virus particle vaccine, εaid protective compound being encoded by εaid nucleic acid εequence.
36. A method to produce a recombinant virus particle vaccine, comprising:
(a) co-transfecting a host cell with a packaging-defective recombinant molecule and an alphavirus packaging vector, wherein said packaging-defective recombinant molecule compriεeε a nucleic acid εequence that encodeε at leaεt one protective compound, said nucleic acid εequence being operatively linked to a packaging-defective alphaviruε expression vector, wherein said packaging vector is able to effect packaging of said packaging-defective recombinant molecule into a recombinant virus particle comprising εaid packaging-defective recombinant molecule packaged into an alphaviruε coat, and wherein packaging vector iε eεsentially incapable of self-packaging; (b) culturing said transfected cell in an effective medium to produce said recombinant virus particle;
(c) recovering said recombinant viruε particle; and (d) formulating a vaccine therefrom.
37. The method of Claim 36, wherein said alphavirus packaging vector comprises PV1.
38. A method to produce a recombinant virus particle vaccine, comprising: (a) transfecting a hoεt cell with a packaging- defective recombinant molecule, wherein εaid packaging- defective recombinant molecule comprises a nucleic acid sequence that encodes at least one protective compound, said nucleic acid sequence being operatively linked to a packaging-defective alphaviruε expreεεion vector, and wherein εaid hoεt cell iε capable of packaging said packaging-defective recombinant molecule into a recombinant virus particle comprising εaid packaging-defective recombinant molecule packaged into an alphaviruε coat;
(b) culturing εaid transfected cell in an effective medium to produce said recombinant virus particle; (c) recovering said recombinant virus particle; and
(d) formulating a vaccine therefrom.
39. A method to protect an animal from toxoplasmoεiε compriεing adminiεtering to εaid animal an effective amount of a recombinant viruε particle vaccine compriεing a packaging-defective recombinant molecule packaged in an alphaviruε coat, εaid packaging-defective recombinant molecule compriεing a nucleic acid sequence encoding a Toxoplaεma gondii P30 antigen operatively linked to a packaging-defective Sindbis virus expresεion vector capable of directing replication and expreεεion of εaid packaging- defective recombinant molecule.
40. A recombinant molecule capable of directing expreεεion of at leaεt one protective compound when εaid recombinant molecule iε tranεfected into an animal hoεt cell, εaid recombinant molecule compriεing a nucleic acid εequence encoding at leaεt one protective compound εelected from the group consisting of a protective protein and a protective RNA species, said nucleic acid sequence being operatively linked to an alphavirus expreεεion vector, εaid compound being capable of protecting an animal from disease caused by a paraεite.
41. The recombinant molecule of Claim 40, wherein εaid paraεite iε εelected from the group conεisting of a protozoan, a helminth, an ectoparasite, a funguε, a bacterium, a virus and a combination thereof.
42. The recombinant molecule of Claim 40, wherein said parasite iε εelected from the group conεiεting of
Toxoplaεma , Dirofilaria , Acanthocheilonema , Babeεia , Brugia , Candida , Cryptococcuε , Cryptoεporidium ,
Dipetalonema , Eimeria , Encephalitozoon , Hepatozoon , Hiεtoplaεma , Iεoεpora , Loa , Microεporidia , Neoεpora , Noεema , Onchocerca , Parafilaria , Plaεmodium, Pneumocyεtiε , Rochalimaea , Setaria , Stephanofilaria , Theileria and Wuchereria .
43. The recombinant molecule of Claim 40, wherein εaid paraεite is selected from the group consisting of Toxoplaεma , Dirofilaria and a combination thereof.
44. The recombinant molecule of Claim 40, wherein said protective compound comprises a T . gondii P30 antigen.
45. The recombinant molecule of Claim 44, wherein said T . gondii P30 antigen compriseε a modified T. gondii P30 antigen εelected from the group conεiεting of a P30 antigen lacking amino terminal hydrophobic reεidueε, a P30 antigen lacking carboxyl terminal hydrophobic reεidues and a P30 antigen lacking both amino terminal and carboxyl terminal hydrophobic residues.
46. The recombinant molecule of Claim 44, wherein said T . gondii P30 antigen is εelected from the group conεiεting of P30.336, P30.308, P30.291, P30.289, P30.263, P30.261, P30.257, GST-P30.336, GST-P30.308, GST-P30.291, GST-P30.289, GST-P30.263, GST-P30.261, GST-P30.257, and a combination thereof.
47. The recombinant molecule of Claim 40, wherein said protective protein further comprises a fusion segment.
48. The recombinant molecule of Claim 47, wherein εaid fusion segment is selected from the group consisting of a glutathione binding domain, a metal binding domain, an immunoglobulin binding domain and a sugar binding domain.
49. The recombinant molecule of Claim 40, wherein said protective protein further comprises a signal segment capable of promoting secretion of said protective protein.
50. The recombinant molecule of Claim 49, wherein said signal segment is selected from the group consisting of tissue plasminogen activator, interferon, interleukin, growth hormone, hiεtocompatibility and viral εignal εegments.
51. The recombinant molecule of Claim 40, wherein εaid alphaviruε expreεεion vector iε εelected from the group conεiεting of a Sindbiε viruε expreεεion vector, a Semliki Foreεt viruε expreεsion vector, a Rosε River virus expresεion vector, a Venezuela equine encephalitis virus expression vector or wherein said alphaviruε expreεεion vector compriεeε a hybrid of any one or more of εaid alphaviruε expression vectors.
52. The recombinant molecule of Claim 40, wherein εaid alphavirus expresεion vector iε εelected from the group consisting of SV1, SV2 , SV3, SV4, SV5 and SV6.
53. The recombinant molecule of Claim 40, wherein said alphaviruε expreεεion vector further compriεeε an alphaviruε εubgenomic promoter operatively linked to εaid nucleic acid εequence.
54. The recombinant molecule of Claim 40, wherein εaid alphaviruε expreεεion vector compriεeε a Sindbiε virus expression vector having a Sindbis virus subgenomic promoter and wherein said nucleic acid sequence encodes a T. gondii P30 antigen.
55. The recombinant molecule of Claim 54, wherein said antigen further compriseε a signal segment capable of promoting secretion of said protective protein.
56. The recombinant molecule of Claim 55, wherein said signal segment compriseε a tissue plasminogen activator εignal segment.
57. The recombinant molecule of Claim 54, wherein said antigen further comprises a fusion segment.
58. The recombinant molecule of Claim 57, wherein εaid fuεion εegment iε selected from a glutathione binding domain and a poly-histidine segment.
59. The recombinant molecule of Claim 40, wherein said nucleic acid sequence is selected from the group conεiεting of nP30.1008, nP30.924, nP30.873, nP30.789, nP30.771, nP30.924SS, nP30.867SS, nP30.783SS, nP30.771SS, nGST-nP30.1008, nGST-nP30.924 , nGST-nP30.873 , nGST- nP30.789, nGST-nP30.771, nGST-nP30.924SS, nGST-nP30.867SS, nGST-nP30.783SS, nGST-nP30.771SS and combinationε thereof.
60. The recombinant molecule of Claim 40, wherein εaid recombinant molecule iε selected from the group consiεting of an alphaviruε expreεεion vector εelected from the group consisting of SV1, SV2, SV3 , SV4 , SV5 and SV6 operatively linked to at leaεt one nucleic acid sequence selected from the group consisting of nP30.1008, nP30.924, nP30.873, nP30.789, nP30.771, nP30.924SS, nP30.867SS, nP30.783SS, nP30.771SS, nGST-nP30.1008, nGST-nP30.924, nGST-nP30.873, nGST-nP30.789, nGST-nP30.771, nGST- nP30.924SS, nGST-nP30.867SS, nGST-nP30.783SS and nGST- nP30.771SS.
61. The recombinant molecule of Claim 40, wherein said animal host cell is selected from the group consisting of a mammalian cell, an insect cell, and an avian cell.
62. A recombinant molecule comprising an alphavirus expresεion vector operatively linked to a nucleic acid εequence encoding a fuεion protein, εaid fuεion protein compriεing a fuεion εegment joined to a protein heterologouε to εaid alphaviruε.
63. A recombinant cell capable of producing at leaεt one compound capable of protecting an animal from diεeaεe cauεed by a paraεite, εaid cell comprising an animal cell transfected with a recombinant molecule capable of directing expression of said protective compound, said recombinant molecule comprising a nucleic acid sequence capable of encoding at least one protective compound operatively linked to an alphavirus expreεεion vector.
64. The recombinant cell of Claim 63, wherein said animal cell is εelected from the group consisting of mammalian, insect and avian cells.
65. The recombinant cell of Claim 63, wherein said recombinant cell is transfected with at least one recombinant molecule comprising an alphaviruε expreεεion vector selected from the group consiεting of SV1, SV2, SV3 , SV4 , SV5 and SV6 operatively linked to at least one nucleic acid sequence selected from the group consiεting of nP30.1008, nP30.924, nP30.873, nP30.789, nP30.771, nP30.924SS, nP30.867SS, nP30.783SS, nP30.771SS, nGST- nP30.1008, nGST-nP30.924, nGST-nP30.873, nGST-nP30.789, nGST-nP30.771, nGST-nP30.924SS, nGST-nP30.867SS, nGST- nP30.783SS and nGST-nP30.771SS.
66. A therapeutic composition capable of protecting an animal from disease caused by a parasite when said composition iε administered to said animal in an effective amount, said compoεition being produced by a method compriεing:
(a) culturing an animal cell tranεfected with a recombinant molecule to produce at leaεt one compound
•capable of protecting said animal from said disease, said recombinant molecule comprising a nucleic acid sequence capable of encoding at leaεt one protective compound operatively linked to an alphaviruε expreεsion vector, said compound being selected from the group conεiεting of a protective protein and a protective RNA εpecieε;
(b) recovering εaid protective compound; and (c) formulating a therapeutic compoεition therefrom.
67. The compoεition of Claim 66, wherein εaid protective protein further compriεes a fusion segment.
68. The composition of Claim 66, wherein said protective protein further comprises a signal segment capable of promoting secretion of said antigen from said transfected cell.
69. The composition of Claim 66, wherein said composition further compriseε an immunopotentiator.
70. The composition of Claim 66, wherein said protective compound is selected from the group consisting of P30.336, P30.308, P30.291, P30.289, P30.263, P30.261, P30.257, GST-P30.336, GST-P30.308, GST-P30.291, GST- P30.289, GST-P30.263, GS.T-P30.261, GST-P30.257, and combinations thereof.
71. A method to produce a therapeutic composition capable of protecting an animal from diseaεe caused by a parasite, said method compriεing:
(a) culturing an animal cell transfected with a recombinant molecule to produce at leaεt one compound capable of protecting εaid animal from said diseaεe, εaid recombinant molecule compriεing a nucleic acid sequence capable of encoding at least one protective compound operatively linked to an alphaviruε expreεεion vector;
(b) recovering εaid protective compound; and
(c) formulating a therapeutic compoεition therefrom.
72. A method to protect an animal from a diεeaεe cauεed by a paraεite comprising administering to said animal an effective amount of a therapeutic composition produced by a method comprising: (a) culturing an animal cell transfected with a recombinant molecule to produce a compound capable of protecting said animal from said diεease, said recombinant molecule comprising a nucleic acid sequence capable of encoding at leaεt one protective compound operatively linked to an alphavirus expresεion vector;
(b) recovering said protective compound; and
(c) formulating a therapeutic composition therefrom.
73. The method of Claim 72, wherein εaid animal iε selected from the group conεiεting of mammalε, inεectε, and birdε.
74. The method of Claim 72, wherein said composition is capable of protecting said animal from toxoplasmoεis or heartworm.
75. A method to protect an animal from toxoplasmosis comprising adminiεtering to said animal an effective amount of a therapeutic composition produced by a method compriεing: (a) culturing an animal cell transfected with a recombinant molecule to produce a T . gondii P30 antigen, said recombinant molecule compriεing at leaεt one nucleic acid εequence encoding εaid antigen operatively linked to an alphaviruε expression vector;
(b) recovering said antigen; and
(c) formulating a therapeutic composition therefrom.
76. The method of Claim 63, wherein said antigen comprises a modified T . gondii P30 antigen selected from the group consisting of a P30 antigen lacking amino terminal hydrophobic residueε, a P30 antigen lacking carboxyl terminal hydrophobic reεidues, and a P30 antigen lacking both amino terminal and carboxyl terminal hydrophobic residueε.
77. A method to produce a recombinant molecule compriεing operatively linking a nucleic acid εequence capable of encoding at least one protective compound to an alphaviruε expresεion vector capable of directing expreεsion of εaid recombinant molecule to obtain a recombinant molecule.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1541493A | 1993-02-08 | 1993-02-08 | |
US015414 | 1993-02-08 | ||
PCT/US1994/001398 WO1994017813A1 (en) | 1993-02-08 | 1994-02-08 | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6172194A true AU6172194A (en) | 1994-08-29 |
Family
ID=21771266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU61721/94A Abandoned AU6172194A (en) | 1993-02-08 | 1994-02-08 | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
Country Status (3)
Country | Link |
---|---|
US (1) | US5766602A (en) |
AU (1) | AU6172194A (en) |
WO (1) | WO1994017813A1 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE440957T1 (en) * | 1993-09-15 | 2009-09-15 | Novartis Vaccines & Diagnostic | RECOMBINANT ALPHAVIRUS VECTORS |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
WO1996017072A2 (en) * | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
FR2729960A1 (en) * | 1995-01-30 | 1996-08-02 | Bio Merieux | TOXOPLASMA GONDII MIMOTOPE POLYPEPTIDES AND APPLICATIONS |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US6465634B1 (en) | 1996-04-05 | 2002-10-15 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
FR2750865B1 (en) * | 1996-06-27 | 1998-12-04 | Rhone Merieux | RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS |
EP2298900A1 (en) | 1996-09-17 | 2011-03-23 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
US6372887B1 (en) * | 1996-11-07 | 2002-04-16 | Heska Corporation | Flea serine protease inhibitor proteins |
US6432699B1 (en) | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
AU745183B2 (en) | 1997-10-20 | 2002-03-14 | Bayer Corporation | Neospora vaccines |
US6197502B1 (en) | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
CA2325564A1 (en) | 1998-03-27 | 1999-10-07 | Cytos Biotechnology Ag | Inducible alphaviral gene expression system |
JP2002521461A (en) | 1998-07-29 | 2002-07-16 | インビトロゲン・コーポレーション | Regulated expression of recombinant proteins using RNA viruses |
BR9915771A (en) * | 1998-11-30 | 2001-12-26 | Cytos Biotechnology Ag | Orderly molecular presentation of antigens, preparation process and use |
EP1947112B1 (en) | 1999-04-09 | 2012-05-16 | Heska Corporation | Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof |
WO2000061772A2 (en) | 1999-04-14 | 2000-10-19 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
PT1212045T (en) | 1999-08-24 | 2016-11-22 | Abic Biological Laboratories Ltd | A vaccine composition and method of using the same |
US6592869B2 (en) * | 1999-08-24 | 2003-07-15 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
JP2003512077A (en) | 1999-10-26 | 2003-04-02 | インターナショナル エイズ バクシーン イニシアティブ | Invasive bacteria expressing alphavirus replicon |
WO2001042442A2 (en) | 1999-12-10 | 2001-06-14 | Cytos Biotechnology Ag | Activation of endogenous genes by genomic introduction of a replicon |
WO2001085208A2 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
DE60135983D1 (en) | 2000-05-31 | 2008-11-13 | Novartis Vaccines & Diagnostic | PROCESS FOR CLEANING ALPHAVIRAL REPLICANT PARTICLES |
US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
AU2001290642A1 (en) * | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US7094409B2 (en) * | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
AU2002254174A1 (en) * | 2001-03-13 | 2002-09-24 | Vical Incorporated | Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
CA2460269C (en) | 2001-09-06 | 2013-01-15 | Alphavax, Inc. | Alphavirus replicon vector systems |
US7115266B2 (en) * | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
BR0213117A (en) | 2001-10-05 | 2004-09-21 | Cytos Biotechnology Ag | Angiotensin-vehicle peptide conjugates and their uses |
US20030219459A1 (en) * | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
ATE489969T1 (en) * | 2002-06-20 | 2010-12-15 | Cytos Biotechnology Ag | PACKAGED VIRUS-LIKE PARTICLES IN COMBINATION WITH CPG FOR USE AS ADJUVANTS WITH ALLERGENS. MANUFACTURING PROCESS AND USE |
EP1532167B1 (en) * | 2002-07-17 | 2012-01-25 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
NZ537003A (en) | 2002-07-18 | 2008-03-28 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
SI1524994T1 (en) | 2002-07-19 | 2011-08-31 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays |
JP4991108B2 (en) * | 2002-12-13 | 2012-08-01 | アルファバックス,インコーポレイティド | Multi-antigenic alphavirus replicon particles and methods |
ES2552687T3 (en) * | 2002-12-13 | 2015-12-01 | Alphavax, Inc. | Alpha Particles and Preparation Methods |
KR101518309B1 (en) * | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | Improved alphavirus replicons and helper constructs |
US20070087331A1 (en) * | 2003-05-15 | 2007-04-19 | Cytos Biotechnology Ag | Selection of b cells with specificity if interest: method of preparation and use |
AU2004257214B2 (en) * | 2003-07-11 | 2010-04-22 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
US20050043517A1 (en) * | 2003-08-20 | 2005-02-24 | Jill Giles-Komar | Method for generating antibodies |
WO2005026316A2 (en) * | 2003-09-15 | 2005-03-24 | Bioption Ab | Alphavirus vaccines |
CA2553594A1 (en) * | 2004-01-20 | 2005-07-28 | Cytos Biotechnology Ag | Particle-induced ghrelin immune response |
ES2321212T3 (en) | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | ALFAVIRUS VECTORS DERIVED FROM TC-83, PARTICLES AND METHODS BACKGROUND OF THE INVENTION. |
US20070248617A1 (en) * | 2004-06-02 | 2007-10-25 | Bachmann Martin F | Medical Uses of Carrier Conjugates of Non-Human Tnf -Peptides |
WO2006085983A2 (en) * | 2004-07-09 | 2006-08-17 | University Of North Carolina At Chapel Hill | Viral adjuvants |
US7998733B2 (en) | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
US8486420B2 (en) * | 2005-02-15 | 2013-07-16 | The University Of North Carolina At Chapel Hill | Live virus vaccines |
CN101137674A (en) | 2005-03-08 | 2008-03-05 | 肯顿有限公司 | Chimeric recombinant antigens of toxoplasma gondii |
AU2006305754A1 (en) * | 2005-10-28 | 2007-05-03 | Centocor, Inc. | Use of B cell expansion agents in generating antibodies |
US7850977B2 (en) * | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
WO2012067866A2 (en) | 2010-11-15 | 2012-05-24 | The Board Of Trustees Of The University Of Illinois | Multivalent vaccine for filariasis |
WO2012101509A2 (en) | 2011-01-28 | 2012-08-02 | Sanofi Pasteur Sa | Immunological compositions against hiv |
WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
CN105233306B (en) * | 2015-11-03 | 2019-01-22 | 温州医科大学 | A kind of replication competent type RNA vaccine and construction method and application for toxoplasmosis prevention and treatment |
BR112022015994A2 (en) | 2020-02-13 | 2022-10-11 | Univ Illinois | MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS |
AU2022218139A1 (en) | 2021-02-03 | 2023-09-21 | Pai Life Sciences Inc. | Vaccine and methods for preventing filariasis and dirofilariasis |
CN113604505A (en) * | 2021-08-11 | 2021-11-05 | 华农(肇庆)生物产业技术研究院有限公司 | pSFV-p32 virus-like particle and preparation method and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3940598A1 (en) * | 1989-12-08 | 1991-06-13 | Behringwerke Ag | TOXOPLASMA GONDII-ANTIGENE, THEIR PRODUCTION AND USE |
US4473548A (en) * | 1982-07-30 | 1984-09-25 | The Kansas University Endowment Association | Method of immunizing cats against shedding of Toxoplasma oocysts |
US4391822A (en) * | 1982-07-30 | 1983-07-05 | Kansas University Endowment Association | Method for preventing cats from shedding Toxoplasma oocysts after infection of such cats |
US4473549A (en) * | 1982-07-30 | 1984-09-25 | The Kansas University Endowment Association | Method for the immunization of animals and men against Toxoplasma gondii _ |
US4564592A (en) * | 1983-01-21 | 1986-01-14 | Research Corporation | Toxoplasmosis factor and production of same |
US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
NZ224663A (en) * | 1987-05-28 | 1990-11-27 | Amrad Corp Ltd | Fusion proteins containing glutathione-s-transferase and expression of foreign polypeptides using glutathione-s-transferase encoding vectors |
FR2633309B1 (en) * | 1988-06-24 | 1992-04-24 | Pasteur Institut | DNA SEQUENCE ENCODING PROTEIN P30 OF TOXOPLASMA GONDII, EXPRESSION PRODUCTS THEREOF, PROCESSES FOR OBTAINING SAME AND APPLICATIONS THEREOF |
JPH02261382A (en) * | 1989-04-03 | 1990-10-24 | Mochida Pharmaceut Co Ltd | Novel dna sequence originated from toxoplasma and protein coded therewith |
US5045313A (en) * | 1989-07-07 | 1991-09-03 | The University Of Kansas | Vaccine for immunizing cats against toxoplasma oocyst shedding |
GB9027728D0 (en) * | 1990-12-20 | 1991-02-13 | Smithkline Beecham Biolog | Novel protein |
-
1994
- 1994-02-08 WO PCT/US1994/001398 patent/WO1994017813A1/en active Application Filing
- 1994-02-08 AU AU61721/94A patent/AU6172194A/en not_active Abandoned
-
1995
- 1995-01-19 US US08/375,235 patent/US5766602A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5766602A (en) | 1998-06-16 |
WO1994017813A1 (en) | 1994-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6172194A (en) | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens | |
US20030091591A1 (en) | Alphavirus expression vectors and uses thereof | |
KR101255016B1 (en) | Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof | |
Schmaljohn et al. | Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins | |
KR0156545B1 (en) | Recombinant coccidiosis vaccines | |
EP1751178A2 (en) | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein | |
JPH06501845A (en) | Expression of human CMV glycoprotein-H using a baculovirus-insect cell expression system | |
CA2336587A1 (en) | Botulinum neurotoxin vaccine | |
KR20160135740A (en) | Recombinant isfahan viral vectors | |
Osorio et al. | Recombinant raccoon pox vaccine protects mice against lethal plague | |
KR102165100B1 (en) | Virus-like particles expressing toxoplasma gondii rhoptry protein, and pharmaceutical composition comprisimg the same | |
JP7387623B2 (en) | Recombinant virus that can stably express target proteins | |
EP3600399A1 (en) | Methods and compositions for vaccinating against malaria | |
KR20230172527A (en) | Alphavirus vector containing universal cloning adapter | |
Yinchang et al. | The protective immunity produced in infected C57BL/6 mice of a DNA vaccine encoding Schistosoma japonicum Chinese strain triose-phosphate isomerase | |
US20070190065A1 (en) | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein | |
Thomsen et al. | Applications of insect cell gene expression in pharmaceutical research | |
WO1998024912A2 (en) | Recombinant plague vaccine | |
Yang et al. | Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus | |
KR20210082306A (en) | Development of recombinant subunit Zika virus vaccine and preparing method thereof | |
CN113913393B (en) | Novel recombinant newcastle disease virus vaccine for coronavirus pneumonia | |
JP3428666B2 (en) | Recombinant Marek's disease virus and its production | |
WO2001055181A2 (en) | Recombinant multivalent malarial vaccines against plasmodium vivax | |
KR102243295B1 (en) | Recombinant vaccine composition comprising envelope protein of Zika virus | |
AU634512B2 (en) | Expression of the plasmodium circumsporozoite protein in insect cells |